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Abstract 
Periodontitis is a globally significant disease which destroys the attachment tissues and alveolar bone of teeth, eventually leading to tooth 
loss. Biofilms, the most intrinsic lifestyle of bacteria, play a pivotal role in the occurrence of this disease. Periodontal biofilms can be treated 
with topically administered chlorhexidine and strain-specific antibiotics. However, these antimicrobials do not offer solutions for periodontal 
attachment tissue and alveolar bone loss. Some therapeutical alternatives for these conventional treatments have been investigated. In 
numerous studies, periodontitis is treated successfully (increased attachment and/or alveolar bone levels) with topically and systemically 
administered bisphosphonates. Furthermore, a topically administered bone graft substitute (bioactive glass) has shown to improve periodontal 
parameters. In addition, bioactive glass has known antimicrobial and anti-biofilm effects. Moreover, a few bisphosphonates have shown 
antimicrobial activity against some bacterial strains. Hence, both bisphosphonates and bioactive glass are promising materials for dental 
applications, also raising interest in their combination. Indeed, it could be hypothesized that this combination product could simultaneously 
treat both the underlying cause (biofilms) and consequences (alveolar bone and attachment tissue loss) of periodontitis. 
Open research questions remain for the combination product. Is the anti-biofilm effect enhanced when bioactive glass is combined with 
bisphosphonates? Moreover, do bisphosphonates have intrinsic anti-biofilm properties? These questions are investigated in this thesis, which 
is a continuation of a recent doctoral dissertation. In this dissertation, a clodronate-bioactive glass combination product was studied by 
applying it into periodontal pockets. However, anti-biofilm effects were not assessed. In this thesis, a close examination is carried out on these 
effects, utilizing relevant biofilm models. 
The aims of this work were to investigate anti-biofilm effects of bisphosphonates (alendronate, clodronate, etidronate, risedronate and 
zoledronate) (i) alone, administered as solutions and (ii) combined with bioactive glass S53P4. Optimization of the used assay methods (96-
well plate assay, Static Biofilm method) was performed. The anti-biofilm effects of bisphosphonate solutions were screened in the 96-well 
plate assay using a model organism Staphylococcus aureus Newman and a periodontopathogen Aggregatibacter actinomycetemcomitans 
ATCC 33384. After this, experiments were conducted with bisphosphonate-bioactive glass combinations. The experiments were performed 
with a single-specie (A. actinomycetemcomitans ATCC 33384) dental biofilm model based on the Static Biofilm method. The model mimics 
conditions encountered by periodontal bacteria in the oral cavity. In this part, bisphosphonate particle sizes were measured to determine a 
suitable control material. In addition to bacterial experiments, pH measurements were carried out to gain an insight to a possible anti-biofilm 
mechanism.  
Bisphosphonates administered as stand-alone compounds did not have an effect on either the Gram-positive model organism (S. aureus 
Newman) or the Gram-negative periodontopathogen (A. actinomycetemcomitans ATCC 33384). In contrast, most combinations of 
bisphosphonate-bioactive glass revealed a statistically significant increase in anti-biofilm effect on A. actinomycetemcomitans ATCC 33384. 
The combinations were compared to a control composed of inert glass and bioactive glass. In these assay conditions, the risedronate-
bioactive glass-combination was the most effective (significant statistical difference, p < 0.05). Other combinations also reduced biofilms 
(significant statistical differences, p < 0.05), with the exception of clodronate-bioactive glass, where the change was not statistically significant. 
The most effective combinations (containing risedronate and etidronate) subjected the biofilms to a period of low pH. Conversely, the least 
effective combination (clodronate-bioactive glass) rapidly became alkaline, similarly to the control compounds (inert glass and bioactive glass). 
Thus, anti-biofilm efficacy could be connected to lowered pH. This observation is supported by recent literature where A. 
actinomycetemcomitans has been deemed highly sensitive to acidity. However, establishing the anti-biofilm rank order of bisphosphonate-
bioactive glass combinations would benefit from experiments with equal bisphosphonate particle sizes.  
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Tiivistelmä 
Parodontiitti on kansainvälisesti merkittävä sairaus, joka tuhoaa hampaan kiinnityskudoksia ja alveoliluuta. Tämä johtaa lopulta hampaan 
irtoamiseen. Biofilmit, bakteereille ominaisin olomuoto, ovat tärkeässä roolissa parodontiitin synnyssä. Parodontiitin biofilmejä voidaan hoitaa 
topikaalisesti annostellulla klooriheksidiinillä ja bakteerikannan mukaisesti valituilla antibiooteilla. Kuitenkaan nämä mikrobilääkkeet eivät 
tarjoa ratkaisuja parodontiitin aiheuttamaan kiinnityskudos- ja alveoliluukatoon. Terapeuttisia vaihtoehtoja näille perinteisille hoitokäytännöille 
onkin tutkittu. Lukuisissa tutkimuksissa parodontiittia on hoidettu onnistuneesti (kasvaneet alveoliluu- ja/tai kiinnityskudostasot) topikaalisesti 
ja systeemisesti annostelluilla bisfosfonaateilla. Myös topikaalisesti annostellulla luun täytemateriaalilla (bioaktiivinen lasi) on saavutettu 
parodontaalistatuksen kohentumista. Tällä materiaalilla on myös todettu olevan mikrobien ja biofilmien vastaista tehoa. Myös eräät 
bisfosfonaatit ovat osoittaneet tehoa muutamia mikrobikantoja vastaan. Näiden seikkojen vuoksi sekä bisfosfonaatit että bioaktiivisen lasi 
ovat lupaavia materiaaleja hammassovelluksissa, ja niiden yhdistäminen onkin herättänyt kiinnostusta. Voidaankin esittää hypoteesi, että 
tällä yhdistelmävalmisteella voidaan hoitaa sekä parodontiitin juurisyytä (biofilmit) että seuraksia (alveoliluu- ja kiinnityskudoskato).  
Yhdistelmävalmisteeseen liittyy kuitenkin avoimia kysymyksiä. Voidaanko biofilmien vastaista vaikutusta parantaa yhdistämällä bioaktiivinen 
lasi bisfosfonaattien kanssa? Onko bisfosfonaateilla itsellään biofilmien vastaista tehoa? Näitä kysymyksiä tutkitaan tässä pro gradu -
tutkielmassa, joka on jatkoa tuoreelle väitöskirjalle. Kyseisessä väitöskirjassa tutkittiin klodronaatista ja bioaktiivisesta lasista muodostettua 
yhdistelmävalmistetta parodontaaliseen ientaskuun annosteltuna. Työssä ei kuitenkaan käsitelty näiden aineiden vaikutuksia biofilmeihin. 
Tässä pro gradu -tutkielmassa näitä vaikutuksia tutkittiin relevantteja biofilmimalleja hyödyntämällä. 
Tämän työn tavoitteina oli kartoittaa bisfosfonaattien (alendronaatti, etidronaatti, klodronaatti, risedronaatti ja tsoledronaatti) vaikutuksia 
biofilmeihin (i) yksin liuoksena annosteltuna ja (ii) yhdessä bioaktiiviseen lasin S53P4 kanssa annosteltuna. Käytettyjä menetelmiä (96-
kuoppalevy- ja Staattinen biofilmimenetelmä) optimoitiin. Bisfosfonaattiliuoksien vaikutuksia malliorganismin (Staphylococcus aureus 
Newman) ja parodontiittipatogeenin (Aggregatibacter actinomycetemcomitans ATCC 33384) biofilmeihin tutkittiin 96-
kuoppalevymenetelmällä. Tämän jälkeen siirryttiin bisfosfonaatti-bioaktiivinen lasi-yhdistelmien tutkimiseen. Näitä tutkittiin yhdestä kannasta 
(A. actinomycetemcomitans ATCC 33384) koostuvalla biofilmimallilla, joka pohjautuu Staattiseen biofilmimenetelmään. Tämä malli kuvastaa 
olosuhteita, jotka parodontiittibakteerit kohtaavat suussa. Tässä osassa suoritettiin myös bisfosfonaattien hiukkaskokomittaus sopivan 
kontrollimateriaalin valitsemiseksi. Bakteeritöiden lisäksi tutkielmaan sisällytettiin pH-mittauksia, joilla selvitettiin mahdollisia biofilmien 
vastaisia mekanismeja.  
Yksikään bisfosfonaattiliuos yksinään annosteltuna ei osoittanut tehoa Gram-positiiviseen malliorganismiin (S. aureus Newman) eikä Gram-
negatiiviseen parodontiittipatogeeniin (A. actinomycetemcomitans ATCC 33384). Sen sijaan, useimmat bisfosfonaatti-bioaktiivinen lasi-
yhdistelmät osoittivat tilastollisesti merkittäviä biofilmien (A. actinomycetemcomitans ATCC 33384) vastaisia vaikutuksia. Yhdistelmiä verrattiin 
kontrolliin, joka koostui inertistä- sekä bioaktiivisesta lasista. Risedronaatti-bioaktiivinen lasi-yhdistelmä oli tehokkain (tilastollisesti merkittävä 
ero, p < 0.05) näissä koeolosuhteissa. Myös useimmat muut yhdistelmät vähensivät biofilmien määrää merkittävästi (tilastollisesti merkittävät 
erot, p < 0.05). Vain klodronaatti-bioaktiivinen lasi-yhdistelmän vaikutus ei ollut tilastollisesti merkittävä. Huomattiin, että tehokkaimmat 
yhdistelmät (etidronaatti- ja risedronaatti-bioaktiivinen lasi) altistivat biofilmit matalan pH:n ajanjaksolle. Sen sijaan vähiten aktiivisella 
yhdistelmällä (klodronaatti-bioaktiivinen lasi) ja kontrollinäytteellä pH muuttui nopeasti emäksiseksi. Täten, biofilmin vastaiset vaikutukset 
voivat olla yhteydessä mataliin pH-arvoihin. Myös tuoreessa kirjallisuudessa on havaittu A. actinomycetemcomitans:n olevan erittäin herkkä 
happamuudelle. Jotta yhdistelmävalmisteet voitaisiin asettaa biofilmien vastaiseen paremmuusjärjestykseen, tulisi jatkotutkimus suorittaa 
samalla bisfosfonaattien hiukkaskoolla. 
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1 INTRODUCTION  
Periodontitis is a significant disease both worldwide (Jin et al. 2011) and in Finland 
(Current Care Guidelines 2010). It destroys the attachment tissues of teeth, eventually 
leading to tooth loss (Giannobile 2008). This tissue destruction is due to an infection-
induced host response inflammation. Biofilms, the most common microbial lifestyle 
(Tortora et al. 2014a) present in diverse environments (Tortora et al. 2014f), play an 
important role in the occurrence of this infection (Giannobile 2008). Biofilms are matrix-
enclosed microbes displaying higher tolerance against external threats than single-cell 
bacteria (Costerton et al. 1999). Periodontitis has been treated successfully with 
bisphosphonates (Rocha et al. 2001; Takaishi et al. 2001; El-Shinnawi and El-Tantawy 
2003; Takaishi et al. 2003; Rocha et al. 2004; Palomo et al. 2005; Reddy et al. 2005; 
Jeffcoat et al. 2007; Veena and Prasad 2010; Pradeep et al. 2012; Sharma and Pradeep 
2012a and 2012b) and bioactive glasses (Mengel et al. 2003; Mengel et al. 2006; Chacko 
et al. 2014). However, bisphosphonate-bioactive glass combinations have not been 
widely investigated. Such combinations are a focal element of this study, which is a 
continuation of Dr. Kirsi Rosenqvist's recent doctoral dissertation (Rosengvist 2014). 
This dissertation focused on the use of a clodronate-bioactive glass combination product 
in the treatment of periodontitis. A clinical trial and a physicochemical characterization 
of the combination product were performed and a potential beneficial effect in protection 
against dental infections was suggested. However, specific studies regarding anti-biofilm 
effects of the combination product were not carried out. The anti-microbial (Stoor et al. 
1998; Leppäranta et al. 2008; Munukka et al. 2008; Drago et al. 2013; Coraça-Huber et 
al. 2014; Gergely et al. 2014; Romanò et al. 2014) and anti-biofilm (Coraça-Huber et al. 
2014; Drago et al. 2014) effects of solely bioactive glass (S53P4) against many strains 
are known in literature. In addition, alendronate, clodronate (Kruszewska et al. 2002) and 
risedronate (Kruszewska et al. 2012) have shown antimicrobial activity against some 
bacterial strains. Similar effects against periodontal biofilms would offer additive benefits 
for the combination product in addition to known positive bone construction effects of 
bioactive glass (S53P4) (Virolainen et al. 1997). In addition to clodronate, this thesis 
extends the anti-biofilm property investigation to include also four other bisphosphonate 
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compounds (alendronate, etidronate, risedronate and zoledronate). In particular, a close 
examination is carried out on specific anti-biofilm effects, using relevant biofilm models.  
The experimental part of the thesis is divided into three parts: the first aims at 
investigating whether bisphosphonates have intrinsic anti-biofilm effects as stand-alone 
compounds. The second part studies the bisphosphonates together with bioactive glass 
S53P4 (BAG) in the combination product, using a single-specie dental biofilm. A well-
known biofilm former organism (Staphylococcus aureus Newman) was used in initial 
tests. Aggregatibacter actinomycetemcomitans ATCC 33384, a reference organism 
known to be a late colonizer in dental plaque, was employed for both parts. For the first 
two parts, there was an additional objective of optimizing experimental methods in the 
study of A. actinomycetemcomitans ATCC 33384.  In the third part, pH measurements 
were utilized to examine mechanistic anti-biofilm actions of bisphosphonates and 
bisphosphonate-BAG combinations on biofilms. 
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2 BACTERIAL BIOFILMS 
2.1 Definition 
Bacteria can exist as single cells or in a multicellular state (Costerton et al. 1995). Single 
cells float or swim in a liquid (Tortora et al. 2014f), and they are called planktonic cells 
(Costerton et al. 1995). Cells that exist in a multicellular, community-based lifestyle are 
called biofilms. In the field of microbiology, planktonic cells have traditionally been the 
point of interest. The significance of biofilms surged during the late 1900’s, when 
Costerton et al. (1978) established a biofilm theory which remains valid to the present 
day. This led to increased research activity within the field. Biofilms are sessile, 
structured bacterial communities surrounded by a self-produced polymeric matrix 
attached to a living or non-living surface (Costerton et al. 1999). In addition to this, 
biofilms also differ phenotypically from their planktonic counterparts (Costerton et al. 
1995). It is estimated that in nature, 99% of bacteria exist in biofilms, making them the 
most common bacterial lifestyle outside laboratory conditions (Tortora et al. 2014a). 
Biofilms can consist of a single or several microbe species (Tortora et al. 2014c).  
2.2 Formation of biofilms 
Biofilm formation includes four main phases. At the initial phase, the planktonic bacteria 
are attached to some abiotic or biotic surface (Phase 1, Figure 1) (Otto 2013). The 
attachment to abiotic surfaces occurs via hydrophobic and electrostatic forces. In the 
attachment to biotic surfaces, e.g. strain-specific surface-anchored proteins display an 
important role. Attachment is followed by bacterial aggregation and proliferation (Phase 
2). Upon attachment, the bacteria begin to produce extracellular polymeric substances, 
which surrounds the bacterial community, leading to a complex that can eventually be 
considered a mature biofilm (Phase 3) (Otto 2008). A mature biofilm may exhibit a 
mushroom-like structure with intermittent channels. The channels offer nutritional access 
to lower bacterial layers (Otto 2013) and an excretion route of toxic waste (Tortora et al. 
2014c). At the final phase, bacteria are detached from the mature biofilm and returned 
into the planktonic phase (Phase 4) (Otto 2013). After detachment, bacteria can 
disseminate to other sites for further colonization. Convective dissemination occurs with 
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the aid of water flow in nature and many industrial settings. In the human body, this 
dissemination can occur via the lymphatic system or the blood stream (Otto 2013).  
 
Figure 1. Biofilm evolution described through different phases (modified from Otto 
2013). 
2.3 Structure of biofilms and functional characteristics 
The self-produced matrix (often called slime) is a barrier between bacteria and their 
external environment (Steinberger and Holden 2005) enclosing the bacterial cells 
(Costerton et al. 1999). The matrix consists of extracellular polymeric substances 
(Steinberger and Holden 2005). Matrix composition varies between and even within 
species, but its main components are lipopolysaccharides, extracellular DNA and 
proteins. The matrix serves as a barrier inhibiting entrance of harmful agents (Costerton 
et al. 1999) but also protects the biofilm from dehydration and prevents the nutrients from 
escaping out of the cell (Tortora et al. 2014a).  
Biofilms have an inherently high tolerance against external threats: humidity, osmotic 
pressure, mechanical stress (Otto 2013), heat, UV radiation (Cos et al. 2010), 
disinfectants (Tortora et al. 2014d), antimicrobial agents and the host immune system 
(Costerton et al. 1999). For example, the required antimicrobial agent concentration for 
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biofilm destruction has been shown to be up to 1000-fold in comparison to planktonic 
bacteria (Tortora et al. 2014c). A few explanations for this tolerance have been suggested 
(Costerton et al. 1999). One hypothesis suggests that antibiotics fail to penetrate into their 
targets inside biofilms since the matrix inhibits the diffusion of antibiotics. According to 
a second explanation, antibiotic susceptibility is dependent on bacterial metabolic state. 
Bacteria in biofilms are in different metabolic states due to the differences in nutrient 
availability. Hence, in some biofilm regions, bacteria are deprived and live in a slow 
growing, metabolically inactive state. Bacteria in this state are not as susceptible to 
antibiotics, which predominantly inhibit the processes of metabolically active cells (Otto 
2006). These phenotypically different subpopulation members are called persister cells, 
and they are particularly tolerant against antimicrobial therapies (Lewis 2010). Finally, it 
is likely that the high tolerance results from a combination of the presently suggested and 
other, yet unknown mechanisms. 
Within a host organism, biofilms release antigens and the host system responds with 
antibodies (Costerton et al. 1999). However, the antibodies are not necessarily capable of 
destroying biofilms, but can cause collateral damage to surrounding tissues. Moreover, 
phagocytosis of biofilms is more difficult than of planktonic cells (Tortora et al. 2014b). 
When biofilm infection is treated with antibiotic therapy, it usually removes the 
symptoms caused by released planktonic bacteria, but fails to eliminate the underlying 
root cause biofilm (Costerton et al. 1999). Cases have been reported where biofilms have 
survived despite several years of aggressive antibiotic therapy (Stoodley et al. 2011). 
After discontinuation of an antibiotic regimen, the remaining biofilm can cause recurrent 
infections (Costerton et al. 1999). As a result, biofilms need to be surgically removed via 
revision surgery. This, in turn, increases the likelihood for the occurrence of a new 
infection due to the repeated use of medical devices during hospitalization (i.e. cathethers, 
implants, valves, etc.). This clearly leads to a negative infection cycle that can be very 
difficult to overcome. 
One presently investigated biofilm destruction method involves the inhibition of quorum 
sensing. Quorum sensing is a phenomenon where independent bacteria communicate with 
each other with a signaling chemical (Tapiainen et al. 2010). This signaling chemical is 
called an inducer (Tortora et al. 2014e). When inducers are diffused into the surrounding 
medium, they attract other bacteria, which start to release inducers of their own. This 
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communication has a pivotal role in biofilm formation (Tapiainen et al. 2010). Upon 
inhibition of quorum sensing, the remaining planktonic bacteria, incapable of forming 
biofilms, are easier to eradicate with antibiotics. Thus, a future prospect is to combine a 
quorum sensing inhibitor and an antibiotic in order to increase the performance of the 
regimen. 
2.4 Clinical relevance of biofilms and connection to diseases 
It is estimated that 70% of bacterial infections are biofilm-mediated (Tortora et al. 2014c). 
This is not surprising, considering the protection that bioﬁlms offer for bacterial survival 
in the host (Otto 2013). Biofilms can colonize indwelling medical devices such as joint 
and bone prostheses, catheters and artificial heart valves (Costerton et al. 1999; Otto 
2013). Other biofilm-mediated infections are e.g. otitis media, osteomyelitis, cystic 
fibrosis, dental caries and periodontitis (Costerton et al. 1999). Periodontitis will be 
discussed in detail in Chapter 3. Biofilms can also be the causes for prolonged otitis media 
and urethritis (Tapiainen et al. 2010). As previously described, biofilm infections are 
often difficult or impossible to eradicate with antibiotics (Parsek and Singh 2003). 
Furthermore, biofilm infections are challenging to diagnose since the sampling and 
recovery of biofilms from tissues is difficult (Tapiainen et al. 2010). On the other hand, 
bodily biofilms can also be beneficial, e.g. in protection from invading pathogens (Tortora 
et al. 2014f). This dual nature exists also from an industrial perspective. While biofilms 
can cause severe problems by clogging industrial pipelines and machines, their controlled 
growth can be utilized in e.g. biosensors, bioremediation applications (pollutant 
detoxification and degradation) (Rodriguez et al. 2012) and for efficient energy 
production. In nature, biofilms in plants provide protection from invading soil pathogens 
(Rudrappa et al. 2008) and act as nutrition for aquatic animals (Tortora et al. 2014f).   
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2.5 Relevant biofilm-forming microorganisms 
2.5.1 Staphylococcus aureus as a model organism 
Staphylococcus aureus (S. aureus) is a Gram-positive bacterium which forms biofilms 
(Otto 2013). One fifth of the Finnish population has S. aureus colonizing their nasal 
cavities (Lumio 2013). S. aureus causes osteomyelitis (Jabra-Rizk et al. 2006), as well as 
skin, wound and post-surgery infections (Lumio 2013). Moreover, it causes sepsis upon 
invasion in the bloodstream (Lumio 2013). It is regarded as a main source of nosocomial 
infections (Jabra-Rizk et al. 2006). S. aureus is associated with many biofilm-mediated 
infections which are tolerant to antimicrobial treatment. Together with Staphylococcus 
epidermis, they are responsible for more than half of prosthetic device-associated 
infections (Fluckiger et al. 2005). Methicillin-resistant S. aureus (MRSA), also resistant 
to other penicillins and kefalosporines, causes infection epidemics in hospitals (Lumio 
2013). 
2.5.2 Aggregatibacter actinomycetemcomitans as a dental pathogen 
Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans, previously 
Actinobacillus actinomycetemcomitans) is a periodontal pathogen (Kesić et al. 2009) 
causing localized aggressive periodontitis i.e. juvenile periodontitis and endocartitis 
(Bhattacharjee et al. 2011). It is a Gram-negative (Mandell and Socransky 1981; Zambon 
et al. 1983), capnophilic (Bhattacharjee et al. 2011), microaerophilic, nonmotile (Mandell 
and Socransky 1981), facultatively anaerobic (Bhattacharjee et al. 2011) rod (Mandell 
and Socransky 1981). This fastidious and slowly growing organism can be grown on 
blood and chocolate agar (Kesić et al. 2009). Bacterial colonization starts after 48–72 
hours of incubation. The incubation temperature is between 20 to 42º C.  
A microaerophilic bacterium requires oxygen, but as concentrations lower than in the 
ambient air (Tortora et al. 2014c). A facultative anaerobe is a bacterium that can grow 
both with and without oxygen. When oxygen is not available, such organisms utilize 
fermentation or anaerobic respiration for energy production. Capnophiles are bacteria that 
grow better at elevated concentrations of carbon dioxide. Low-oxygen, high-carbon 
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dioxide conditions required by A. actinomycetemcomitans can be created with carbon 
dioxide incubators, but also with a simple candle jar technique (Figure 2), which is a long-
known method in microbiology.  
 
Figure 2. Aggregatibacter actinomycetemcomitans ATCC 33384 is incubated on TSAD5 
(tryptic soy agar supplemented with 5% defibrinated sheep blood) plates in candle jars 
(microaerophilic conditions). 
 
In this technique, cultures are transferred into a sealed, air-tight container with a lit candle 
and incubated (Tortora et al. 2014c). The ensuing combustion process consumes oxygen 
and generates carbon dioxide. The candle stops burning when the air of the container 
reaches a lowered oxygen concentration of ca. 17%. Consequently, elevated carbon 
dioxide levels of ca. 3% are acquired. Many pathogenic bacteria require such conditions.  
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2.6 Biofilm investigation methods 
Most of the antimicrobial compounds and their research methods have been developed 
for planktonic bacteria, despite the facts that most bacteria live in biofilms, and that 
infections are usually due to biofilms, not planktonic bacteria (Skogman 2012). The 
unique features of biofilms require the development of reliable and specific research 
methods, which differ from those optimized for planktonic bacteria (Cos et al. 2010). 
Since characteristics of biofilms and planktonic bacteria are totally different, 
investigation methods for planktonic bacteria cannot be conducted for biofilms (Charaf 
et al. 1999; Donlan and Costerton 2002). Thus, anti-biofilm and anti-planktonic effects 
of compounds should be tested using distinct protocols. There is an urgent need for 
reliable anti-biofilm test methods (Sandberg et al. 2008). In addition to reliability, the 
method should be rapid, simple, reasonable in terms of cost and compliant to automation 
from the perspective of screening large compound libraries. Biofilms can be grown with 
liquid and solid-state growth methods. The choice of method is based on the research 
question under interest (Buckingham-Meyer et al. 2007). The main types of solid and 
liquid assays are presented in Table 1.  
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Table 1. Comparison of biofilm models (modified from Blomqvist 2014). Rotating Disk 
reactor figure from (Biosurface Technologies Corporation 2015). Colony Biofilm Model 
figure from Jo and Kim (2013).  
 
Biofilm 
model 
Culture Substratum 
Fluid 
shear 
Material 
examination 
Advantages 
Liquid culture
 
CDC 
Biofilm 
Reactor 
Continuous Various High Possible 
ASTM 
Standard 
Method 
Liquid culture
 
Rotating 
Disk 
Reactor 
Continuous Various Moderate Possible 
ASTM 
Standard 
Method 
Liquid culture
 
Drip 
Flow 
Biofilm 
Reactor 
Continuous Various Low Possible 
ASTM 
Standard 
Method 
Liquid culture
 
MBEC 
Assay 
Batch 
culture 
Plastic pegs Gentle 
Yes, but 
limited by 
well space 
Rapid, HTS, 
ASTM 
Standard 
Method 
Liquid culture
 
Well 
plate 
assays 
Batch 
culture 
Plastic No/Low 
Yes, but 
limited by 
well space 
HTS, fairly 
cheap, user-
friendly 
Solid culture
 
 
Static 
Biofilm 
method 
 
Batch 
culture 
Various No Possible 
Inexpensive, 
removable 
coupons, 
versatile 
Solid culture
  
Colony 
Biofilm 
model  
Continuous 
Polycarbonate 
filter paper 
No Possible 
Antibiotic 
penetration 
through 
biofilms can 
be examined 
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2.6.1 Assays performed in liquid cultures 
ASTM International (American Society for Testing and Materials) is one of the largest 
international organizations developing and providing standard methods (ASTM 
International 2015). There are five ASTM standardized methods for growing (and treating 
in MBEC Assay) biofilms (Table 1): CDC Biofilm Reactor (ASTM International 
Standard E2562-12), Rotating Disk Reactor (ASTM International Standard E2196-12), 
Drip Flow Biofilm Reactor (ASTM International Standard E2647-08), MBEC Assay 
(ASTM International Standard E2799-11) and Single Tube Disinfection (ASTM 
International Standard E2871-13). These methods are primarily standardized for 
Pseudomonas aeruginosa, and can be roughly divided into two culture modes: continuous 
and batch cultures. Continuous culture reactors include the Drip Flow Biofilm Reactor, 
the Rotating Disk Reactor and the CDC Biofilm Reactor. In these cases, a continuous 
ﬂow of the medium ensures that fresh nutrients are always present (Merritt et al. 2005). 
In batch cultures, there is a fixed volume of nutrients, and bacteria may encounter 
nutritional shortage or exhaustion. The MBEC Assay and the widely applied well plates 
are batch cultures. 
In the CDC Biofilm Reactor, bioﬁlms are formed on coupons inserted into rods. In 
addition to the continuous ﬂow of nutrients, biofilms are subjected to high ﬂow shear 
from the rotation of a baffled stir bar. The Rotating Disk Reactor is based on coupons 
inserted into disks, which experience medium flow shear. With the Drip Flow Biofilm 
Reactor, biofilms can be formed on coupon surfaces that are inserted into reactor 
channels. In these conditions, biofilms experience a continuous ﬂow of dripping nutrients 
with a low fluid shear caused by gravity at an inclination angle of 10°. After biofilm 
formation, the efficacy of different anti-biofilm compounds can be examined. 
The MBEC (Minimum Bioﬁlm Eradication Concentration) Assay is a standardized 
screening tool, which allows simultaneous testing of many compounds or compound 
concentrations. The plastic device consists of a lid with 96 pegs and a corresponding 
receiver plate with 96 wells. Bioﬁlms are formed on the pegs with gentle mixing, without 
ﬂow of nutrients into or out of an individual well (batch conditions). The formed biofilms 
are transferred to a new receiver plate for compound efficacy testing.  
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Well plate assays were utilized in this thesis (with 96-well plates). These cheap and user-
friendly well plates are commonly used in the field of biofilms for quick compound 
screening (Peeters et al. 2008; Coenye and Nelis 2010). As in the MBEC Assay, 
simultaneous testing of many compounds and concentrations is possible. Another clear 
benefit is that compound anti-biofilm effects can be investigated with two modes (pre- 
and post-exposure) (Sandberg et al. 2008). The compound can be applied at the same time 
as the biofilm-forming bacterial suspension (pre-exposure), or after the formation (post-
exposure). The purpose of the pre-exposure assay is to investigate whether the compound 
can prevent biofilm formation. This is usually possible using smaller concentrations of 
antibiotics than in post-exposure tests. In contrast, the aim of the post-exposure assay is 
to examine whether the compound can act on pre-formed biofilms. This generally 
requires higher concentrations of antibiotics. Cryopreserved ready-made biofilms in 96-
well plates and well-plate handling automation can be used to facilitate compound 
screening (Sandberg et al. 2008). 
The different assay methodologies are utilized to mimic the fluid dynamics of the target 
environment. This is important since flow shear has an effect on formed biofilm tolerance 
and functional behavior (Buckingham-Meyer et al. 2007). Biofilms formed under high 
shear conditions (turbulent flow) are denser, more stable (Pereira et al. 2002) and more 
resistant to chemical insults when compared with those formed in low shear conditions 
(laminar flow) (Buckingham-Meyer et al. 2007) or planktonic cells (Eginton et al. 1998).  
2.6.2 Assays performed in solid-state cultures 
In solid-state methods, biofilm growth surfaces are not immersed in liquid (Table 1) (Oja 
et al. 2014). They are less frequently used, and include the Colony Biofilm model and the 
Static Biofilm method (Table 1). In the Colony Biofilm model, inoculated polycarbonate 
membrane filters are transferred regularly onto new agar. Thus, it is a continuous culture. 
Instead, the Static Biofilm method consists of biofilms grown on a single agar plate for 
the entire incubation time (batch culture) (Oja et al. 2014). The biofilms are grown in the 
absence of fluid shear (Buckingham-Meyer et al. 2007; Oja et al. 2014). For this reason, 
the method can be considered suitable for mimicking infections e.g. in the ear or the skin 
(Oja et al. 2014). The Static Biofilm method is deemed very versatile, because it offers 
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the possibility to investigate many strains, coupon materials and compounds. It represents 
a robust, simple and economic option, which can be utilized in any basically equipped 
microbiological laboratory without the need of sophisticated instrumentation (Charaf et 
al. 1999).  
2.6.3 Probes for biofilm quantification 
The anti-biofilm effect of a compound can be evaluated by staining biofilms with different 
indicators (probes). Probe effects, e.g. fluorescence or absorbance, can be measured. 
Biofilm viability, biomass and matrix level are examples of attributes that can be inferred 
from the measurements (Skogman 2012). 
For detection of live and dead bacteria in fluorescence microscopy (FM), bacteria are 
stained with fluorescent probes. SYTO® 9 and propidium iodide are fluorescent nucleic 
acid stains emitting green and red light, respectively (Molecular Probes 2004). When 
biofilms are stained with their combination, SYTO® 9 labels all bacteria, with both intact 
and damaged membranes. In contrast, propidium iodide penetrates only into bacteria with 
damaged membranes, concurrently causing a reduction of SYTO® 9. Thus, live bacteria 
with intact cell membranes show as green, whereas dead bacteria with damaged 
membranes display a red color.  
Resazurin staining is used to detect viable cells (Sandberg et al. 2009). Resazurin (7-
hydroxy-3H-phenoxazin-3-one-10-oxide) is itself a non-fluorescent blue redox dye, but 
can be reduced to pink resorufin, which possesses a highly fluorescent ability (Guerin et 
al. 2001). This reduction occurs when cellular metabolic activity is present. Given enough 
time, the resorufin is further reduced to colourless hyrdoresofurin without a fluorescent 
ability (Sandberg et al. 2009). Hence, resazurin use requires that dye concentration and 
incubation time are optimized for each bacterial strain. Optimal exposure times of the dye 
vary between strains, with excessively short exposure yielding statistically poor results 
(Z’ < 0.4). In contrast, overly long incubation times decrease the quality of assay due to 
resorufin reduction, leading to a weak fluorescence signal (decreased Z’-factor and 
signal-to-background (S/B) ratio). This phenomenon is intrinsic for rapidly metabolizing 
bacteria, e.g. S. aureus. Another disadvantage of resazurin staining is the high bacterial 
concentration required (> 107 CFU• mL-1) for the assay to generate a fluorescent signal. 
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Due to this high detection limit, another quantification method should be used instead at 
low bacterial concentrations.  
Crystal violet staining is widely used to quantify biomass (Sandberg et al. 2009). This 
probe functions by absorbance. Its limitations include the fact that it measures only the 
biomass, and does not distinguish dead cells from live ones. Hence, it offers less 
information than resazurin. It is also more laborious compared to the resazurin staining. 
However, (non-invasive) resazurin and crystal violet staining can be performed in 
sequential workflow (Skogman et al. 2012). With this combination, basic information of 
the biocide mechanism of action (bactericidal or detergent-like) can be gained. For 
example, bactericidal effects of compounds can be detected as a decrease of resazurin 
reduction and crystal violet stained mass. Detergent-like actions can be predicted by a 
registered decrease of crystal violet stained biomass that is associated to an absence of a 
corresponding decrease in resazurin reduction. Furthermore, when staining is performed 
sequentially in the same plate, the consumption of tested compounds, reagents, 
consumables and time can be reduced. Both methods can be seen as a first level filter to 
detect promising active hits from large chemical libraries. They are also relatively cheap 
and fast to carry out. 
After the first-level screening, more specific information of bactericidic behavior is often 
desired. This involves a specific investigation into the biofilm matrix structure, which is 
outside the scope of resazurin and crystal violet methods. The biofilm matrix of 
Staphylococcus aureus can be for instance stained using a wheat germ agglutinin-Alexa 
Fluor 488 fluorescent conjugate (Skogman et al. 2012). An antibiotic candidate can lead 
to a reduction of viability and biomass, but this does not conclusively signify anti-biofilm 
effectiveness. For example, Skogman et al. (2012) reported a case, where penicillin G 
caused a reduction of S. aureus viability and biomass. However, it simultaneously led to 
an increased level of the matrix, indicating a likely compensatory mechanism to protect 
the remaining viable cells from further destruction. Matrix level measurements are pivotal 
since infections can easily reappear, if the matrix has not been entirely eradicated.  
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3 PERIODONTITIS 
3.1 Physiology of teeth 
The visible part of the tooth is called a crown (Figure 3) (Honkala 2009a; Honkala 2009c). 
The crown is covered by enamel. At the cervix of the tooth, the enamel becomes a thin 
film called cementum, which covers the root. The cementum is coated by parallel 
collagenous periodontal ligaments, which are attached to alveolar bone of the jaw. 
 
Figure 3. A dissection schematic of tooth structure. 
 
The dentine, the main component of the tooth, is located beneath the enamel (Honkala 
2009c). The structure of the dentine is softer than the enamel. The hardness of the dentine 
is roughly equivalent to other bones in the body, whereas the enamel, mainly composed 
of minerals, is the hardest tissue in human body. Under the dentine is the pulp, which 
includes root canals and the medulla. Blood vessels and nerves enter the pulp via holes 
located on the root tips.  
The attachment tissues of teeth are called periodontium (Honkala 2009b). The 
periodontium consists of gingiva, periodontal ligaments, cementum and alveolar bone. 
The cervix of the tooth is surrounded by the gingiva. The gingiva and the tooth surface 
form a V-shaped gingival pocket. The signs of a healthy periodontium include that the 
gingiva is firm, has a pink color and is tightly attached to the surface of teeth. 
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3.2 Oral microbiology and biofilm formation 
Oral biofilm formation includes several steps. In the first step, a pellicle consisting of 
glycoproteins and proteins is formed onto the tooth surface (Figure 4) (Darveau et al. 
1997). These glycoproteins and proteins originate from saliva and crevicular fluid. The 
pellicle formation starts to occur within a couple of hours from brushing teeth. Pellicles 
enable adhesion of pioneer colonizers, such as Streptococcus gordonii, Streptococcus 
sanguinis, Streptococcus mitis (Peterson et al. 2011), Streptococcus oralis and 
Actinomyces naeslundii (Sánchez et al. 2011). Pioneer colonizers are then followed by 
early colonizers, such as Streptococcus mutans and Veillonella spp. (Peterson et al. 2011). 
These are accompanied by attachment of intermediate, bridging microorganisms 
(Fusobacterium nucleatum) and late colonizers (Aggregatibacter 
actinomycetemcomitans and Porphyromonas gingivalis) (Sánchez et al. 2011), which are 
primarily anaerobic Gram-negative bacteria and responsible for periodontitis (Peterson et 
al. 2011). 
 
Figure 4. The formation steps of oral biofilms (modified from Clais 2014). 
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3.3 Pathology of periodontal disease 
Periodontitis is a significant disease, both worldwide (Jin et al. 2011) and in Finland, with 
a remarkable economic load (Current Care Guidelines 2010). It is estimated that 64 % of 
the over 30 year-old toothed Finnish population have periodontitis (Knuuttila 2004). It is 
a chronic infection-induced inflammatory disease in the oral cavity, which destroys the 
attachment tissues of the teeth (Giannobile 2008). 
Periodontitis is caused by an inflammation of the teeth supporting tissues (Giannobile 
2008). The inflammation is initiated by Gram-negative microbial biofilm infection. When 
the inflammation extends from the gingiva into the bone and periodontal ligaments, it 
causes irreversible loss of their attachment (Figure 5) (Buencamino et al. 2009). Usually, 
periodontitis shows up in the molars of the maxilla (upper jaw) or in the incisors of the 
mandible (lower jaw) (Hiiri 2009a). 
Figure 5. Characteristics of healthy and periodontal teeth. 
 
There are a variety of risk factors associated to periodontitis. These are: an insufficient 
oral hygiene (Axelsson and Lindhe 1981), smoking (Bergström 2006), diabetes mellitus 
(Taylor 2001), immunodeficiency (Holmstrup and Glick 2002), ageing (Schätzle et al. 
2003), the male gender (Kocher et al. 2005), low social-economic position (Klinge and 
Norlund 2005), genetic predisposition (Kinane and Hart 2003), menopause (Buencamino 
et al. 2009) and presence of periodontal pathogens (van Winkelhoff et al. 2002; Demmer 
et al. 2008). 
Accumulated plaque i.e. bacterial mass on the surface of teeth, gum-line and between 
teeth eventually hardens to dental calculus (Hiiri 2009b). Plaque is mineralized by the 
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calcium- and phosphorus-ions of saliva, forming the calculus (Meurman et al. 2011). 
Furthermore, the porous calculus increases subsequent bacterial attachment (Könönen 
2012a). Calculus and plaque buildup may cause gingivitis, a reversible inflammation of 
gingiva (Figure 6) (Hiiri 2009b). Gingivitis affects 74% of the Finnish adult population. 
This, if untreated, may result in non-reversible periodontitis (Giannobile 2008; 
Buencamino et al. 2009). 
 
Figure 6. Progression from healthy teeth into gingivitis and periodontitis (modified from 
Clais 2014). 
 
Inflammation loosens the tissue connection between tooth and gingiva, deepening the 
periodontal pocket (Meurman 2003; Meurman et al. 2011). The deeper periodontal 
pockets enable bacterial plaque to intrude deeper, making cleaning more difficult. There 
is no clear threshold between gingivitis and periodontitis. While the two involve similar 
microbes, the extent of anaerobic bacteria is larger in periodontitis due to the deeper 
pockets. The periodontal attachment tissue loss is primarily due to host response rather 
than direct bacterial damage (Graves and Cochran 2003). The host response refers to 
defense mechanisms used against exogenous microorganisms. The host response is 
initiated by bacterial lipopolysaccharides, which are present in the outer membrane of 
Gram-negative bacteria as a main component (Giannobile 2008). They trigger 
macrophages to release proinflammatory cytokines, which stimulate the bone resorption 
and tissue attachment loss with proteolytic enzymes.  
 19   
 
Periodontopathogens are usually Gram-negative and strictly or facultatively anaerobic, 
or microaerobic (Könönen et al. 2007). Pathogens associated in periodontitis are 
Aggregatibacter actinomycetemcomitans, Porphyromonas gingivalis, Tannerella 
forsythia (van Winkelhoff et al. 2002; Demmer et al. 2008), Treponema denticola 
(Demmer et al. 2008), Fusobacterium nucleatum, Micromonas micros, Prevotella 
intermedia (van Winkelhoff et al. 2002) and possibly Campylobacter rectus and Eikenella 
corrodens (Demmer et al. 2008). B. forsythus and P. gingivalis are rarely present in 
people without periodontitis (van Winkelhoff et al. 2002). Some periodontal bacteria such 
as A. actinomycetemcomitans and Prevotella nigrescens can be transmitted to a child 
from infected parents (Honkala 2009d). Adulthood transmission (P. gingivalis) is also 
possible, even though the normal flora tends to repel the new bacteria. Saliva, mouth 
mucosa and plaque are relevant transmission routes. 
The symptoms of periodontitis are increased periodontal pocket depth, redness, swelling 
and bleeding of gingiva especially during brushing teeth (Current Care Guidelines 2010). 
Visual observations include gums that are pulled away from teeth and teeth that do not fit 
together (Buencamino et al. 2009). Moreover, increased mobility of teeth, migrated teeth, 
formed gaps, loss of a tooth and discharge are symptoms of advanced periodontitis 
(Current Care Guidelines 2010). Persistent halitosis (Buencamino et al. 2009) and bad 
taste in the mouth can be consequences of periodontitis (Könönen 2012b). The disease 
can also be symptomless, particularly among smokers (Current Care Guidelines 2010) 
because of constricted blood vessels (Hiiri 2009b). Periodontitis does not usually cause 
pain, which can later emerge in a stage of abscess (Meurman et al. 2011). 
Periodontitis can be investigated by measuring periodontal pocket depth and bleeding on 
probing (Current Care Guidelines 2010). Increased pocket depth is defined as a minimum 
of 4 millimeters measured from the gingival margin to the gingival pocket base. In 
addition, X-ray imaging can be used to examine the loss of alveolar bone (≥ 2 mm). 
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3.4 Treatment of periodontal disease 
In addition to the possible tooth loss, periodontitis has a systemic impact on the body. It 
can cause systemic inflammation (Paraskevas et al. 2008) and increases the risk for 
cardiovascular diseases (Pussinen et al. 2007) such as atherosclerosis and coronary heart 
disease (Mustapha et al. 2007; Friedewald et al. 2009). Management of periodontitis 
improves the glycemic control of type II diabetic patients (Teeuw et al. 2010). 
Periodontitis can also show as a first clinical sign of HIV-infection (Holmstrup and 
Westergaard 1994). Thus, control strategies for periodontal disease are essential for 
health maintenance.  
First, a good oral hygiene is pivotal in the prevention of gingivitis and periodontitis 
(Current Care Guidelines 2010). A powered toothbrush is more effective to reduce plaque 
than a manual toothbrush (Robinson et al. 2005; Yaacob et al. 2014). Brushing combined 
with floss (Terézhalmy et al. 2008) or interdental brushes (Slot et al. 2008) removes 
plaque significantly better than brushing alone. Interdental brushes remove plaque 
significantly better when compared to floss (Slot et al. 2008). 
Early diagnosis of periodontitis is crucial so that tooth loss can be prevented (Buencamino 
et al. 2009). After diagnosis, mechanical debridement (scaling and root planing) is 
performed (Current Care Guidelines 2010). Scaling and root planing cleans dental 
calculus and bacterial plaque from infected periodontal pockets, and is performed 
manually or with the aid of an ultrasonic cleaning device. Advanced periodontitis may 
require gingival surgery, which removes infected tissue and offers access to deep 
periodontal pockets. Smoking worsens the treatment prognosis, so patients are 
encouraged to quit smoking. Patient compliance to better domestic oral hygiene is 
important. Topical chlorhexidine and strain-specific systemic antibiotic therapy are 
needed in many cases. The aims of the treatment are reduction of inflammation and pocket 
depths, prevention of further alveolar bone loss and regeneration of alveolar bone and 
increased attachment. These periodontal parameters have been affected positively with 
topical or systemic bisphosphonates (Rocha et al. 2001; Takaishi et al. 2001; El-Shinnawi 
and El-Tantawy 2003; Takaishi et al. 2003; Rocha et al. 2004; Palomo et al. 2005; Reddy 
et al. 2005; Jeffcoat et al. 2007; Veena and Prasad 2010; Pradeep et al. 2012; Sharma and 
Pradeep 2012a and 2012b).  
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4 BISPHOSPHONATES 
Bisphosphonates (BPs) are used to treat various bone diseases with excessive bone 
resorption such as osteoporosis, Paget’s bone disease, osteolytic metastases and 
hypercalcemia of malignancy (Terveysportti: Lääkkeet ja hinnat 2015). Bisphosphonates 
can be administered orally (per os; p.o.) or intravenously (intravenalis; iv.). The 
bisphosphonates of this thesis along with approved doses and indications are presented in 
Table 2. 
Table 2. Indications and approved doses of bisphosphonates used in the thesis (Hillilä 
2007; Terveysportti: Lääkkeet ja hinnat 2015). 
Bisphosphonate Indication Dosing regimen 
Alendronate 
Osteoporosis in men and in post-
menopausal women, and in osteoporosis 
associated with the long-term 
glucocorticoid treatment 
10 mg p.o. daily or  
70 mg p.o. once a 
week 
Etidronate Not approved in Finland 
400 milligrams p.o. 
daily for 14 days 
every three months 
Clodronate 
Osteolytic bone metastases and 
hypercalcemia associated with cancer 
1600–3200 mg p.o.  
Risedronate 
Osteoporosis in men and in post-
menopausal women 
35 mg p.o. once a 
week 
Zoledronate 
1) Paget’s bone disease, osteoporosis in 
men and in post-menopausal women, and 
in osteoporosis associated with the long-
term glucocorticoid treatment 2) in cancer 
to prevent bone incidence and to treat 
hypercalcemia 
1) 5 mg infusion iv. 
once a year 
2) 4 mg infusion iv. 
every 3.–4. week 
 
The optimal treatment durations are not defined, and are evaluated according to gained 
risks and benefits (Terveysportti: Lääkkeet ja hinnat 2015).  
4.1 Structure and classification 
Bisphosphonates are analogues of inorganic pyrophosphates (Rodan 1998). 
Pyrophosphates are endogenous in blood serum, regulating mineralization of bones and 
chelating calcium (Russell 2007). Bisphosphonates have a P–C–P-backbone instead of 
the P–O–P found in pyrophosphates (Figure 7) (Rodan 1998; Mitsuta et al. 2002). Hence, 
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they have two phosphate (PO3) groups covalently linked to the same carbon (Otomo-
Corgel 2007). P–C–P-bonds render bisphosphonates resistant to metabolic enzymatic 
hydrolysis (Castrén-Kortekangas et al. 1997). The basic structure is similar for all 
bisphosphonates, but two side chains (R1 and R2), attached to the central carbon, vary 
between them (Table 3). The R1 chain influences bisphosphonate affinity to 
hydroxyapatite of the bone. A hydroxyl (–OH) R1 group (present in most 
bisphosphonates), rather than a halogen atom (present in clodronate), increases this 
affinity (Russell 2007).  
 
 
 
Figure 7. Structure of pyrophosphate (left) and the general structure of bisphosphonates 
(right) (according to Favus 2010). 
 
Bisphosphonates are divided into three groups according to their structure (Ganapathy et 
al. 2012). The first group includes tiludronate, clodronate and etidronate, whose side 
chains do not include nitrogen (Table 3). Tiludronate differs from clodronate and 
etidronate due to its cyclic side chain. The second group includes alendronate, 
ibandronate, olpadronate and pamidronate due to the nitrogen-involvement in their side 
chains. Furthermore, side chains are not cyclic in the second group. The third group 
includes risedronate and zoledronate. They have cyclic nitrogen-containing side chains.  
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Table 3. Bisphosphonate classification and their side chains (modified from Ganapathy 
et al. 2012). The compounds with * are in clinical use in Finland (Terveysportti: Lääkkeet 
ja hinnat 2015). 
  
Another, simpler way is to divide bisphosphonates into two groups according to nitrogen-
containing side chain R2 (alendronate, ibandronate, olpadronate, pamidronate, 
risedronate and zoledronate) and non-nitrogen-containing side chain R2 (clodronate, 
etidronate and tiludronate) bisphosphonates (Table 4) (van Beek et al. 2003). This 
division also shows in the pharmacological effects of the compounds. 
 
  
Group Compound R1 side chain R2 side chain 
1. 
Non-
nitrogen-
containing 
BPs 
 
Clodronate* 
 
 
 
 
 
Etidronate 
 
 
 
 
 
Tiludronate 
 
 
 
 
2.  
Alkyl-
amino BPs 
 
Alendronate* 
 
 
 
 
 
Ibandronate* 
 
 
 
Olpadronate   
Pamidronate*   
 
3.  
Hetero-
cyclic-
nitrogen 
BPs 
 
Risedronate* 
 
 
 
 
Zoledronate*  
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4.2 Pharmacological effects 
Bisphosphonates have a very selective pharmacological effect targeting bone tissue 
(Fleisch 2003). This macro-level effect is due to their inherent high affinity to solid phase 
calcium phosphate crystals (hydroxyapatite) of bone. On the bone they attach to 
hydroxyapatite, preventing them from forming, aggregating and slowing their 
dissolution.  
At the micro-level, bisphosphonates prevent the function of osteoclasts (van Beek et al. 
2003). The mechanism of action varies according to whether the bisphosphonate contains 
nitrogen or not. The non-nitrogen-containing bisphosphonates are incorporated 
metabolically into the phosphate chain of adenosine triphosphate (ATP), inhibiting 
protein synthesis and resulting in osteoclast apoptosis. The nitrogen-containing 
bisphosphonates inhibit enzyme farnesyl pyrophosphate synthase (FPPS) in the 
mevalonate pathway (also known as HMG-CoA reductase pathway), causing inhibition 
of the prenylation of small GTP-binding proteins in osteoclasts (Luckman et al. 1998). 
This leads to cytoskeleton disruption and apoptosis. Bisphosphonates are able to interfere 
with these processes since osteoclasts internalize bisphosphonates when they are 
adsorbed to the bone surface (Russell 2007). Nitrogen-containing bisphosphonates (also 
called aminobisphosphonates) are more potent than non-nitrogen-containing compounds 
(Table 4) (van Beek et al. 2003).  
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Table 4. The pharmacological potency factors of different bisphosphonates compared to 
etidronate (Roldán et al. 1998; Watts 1998). 
Bisphosphonate Potency factor Mechanism of action 
Non-nitrogen containing BPs   
Etidronate 1 Incorporation into ATP 
results in osteoclast 
apoptosis 
Clodronate 10 
Tiludronate 10 
Nitrogen containing BPs   
Pamidronate 100  
Inhibition of the enzyme 
FPPS results in 
osteoclast cytoskeleton 
disruption and apoptosis 
Alendronate 100–1,000 
Olpadronate 500–1,000 
Ibandronate 1,000–10,000 
Risedronate 1,000–10,000 
Zoledronate 10,000 + 
 
The destruction of osteoclasts slows the resorption of bone into the bloodstream, meaning 
that calcium and phosphate do not secrete from the bone (Hillilä 2007). Overall, the 
bisphosphonate mechanism of action is inhibition of bone resorption, increase of bone 
mineral density and decrease of bone turnover (Fleisch 2003).  
Typical side effects of oral bisphosphonates are gastrointestinal when taken orally 
(Fleisch 2003). Aminobisphosphonates cause these side effects more frequently (Hillilä 
2007). Compounds administered in high doses, such as etidronate, can inhibit normal 
bone mineralization (Fleisch 2003). Furthermore, severe side effects such as erosion of 
the esophagus (Hillilä 2007) and osteonecrosis of the jaw (Buencamino et al. 2009) have 
occurred. The negative effects on the esophagus can be prevented by taking tablets in an 
upright position and avoiding a prone position for at least half an hour (Terveysportti: 
Lääkkeet ja hinnat 2015). The tablet should be swallowed as a whole to prevent damage 
to oral mucosa with a sufficient amount of water. In most cases of the osteonecrosis of 
the jaw, bisphosphonates had been intravenously administered as high doses in the 
treatment of cancer (Buencamino et al. 2009). Afflicted patients also possessed other 
predisposing risk factors.  
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4.3 Pharmacokinetics 
Bisphosphonates can be administered orally and intravenously (Terveysportti: Lääkkeet 
ja hinnat 2015). When taken orally, it is intrinsic for bisphosphonates to have low 
bioavailability (0-10%) due to poor absorption from the gastrointestinal tract (Fleisch 
2003). The absorption may have inter- and intra-subject variability (Hillilä 2007). Oral 
bisphosphonates should be taken without a meal (Terveysportti: Lääkkeet ja hinnat 2015), 
as presence of food decreases the absorption of bisphosphonates significantly (Fleisch 
2003). The tablets are recommended to be taken at least 30 minutes before the first meal 
of the day, other medications or drinks (excluding water) (Terveysportti: Lääkkeet ja 
hinnat 2015). Coffee, orange juice and some medicines are known to prevent absorption 
(Hillilä 2007). Bisphosphonates can react with divalent cations (Ca2+, Mg2+, Fe2+, Al3+) 
(Terveysportti: Sfinx-Pharao 2015) forming near inabsorbable complexes (Hillilä 2007).  
Right after the absorption from the gastrointestinal tract, 20–80% of absorbed 
bisphosphonate rapidly and selectively distributes to the bone mineral (Fleisch 2003). The 
remaining compound is rapidly eliminated via urine excretion (Fleisch 2003) and does 
not go through metabolic alterations (Hillilä 2007). The elimination of the remaining 
bisphosphonate depends of the metabolic activity of the bone tissue, since the compound 
is released when bone is resorbed (Fleisch 2003). The bone-incorporated compound may 
therefore experience a long terminal half-life. The following terminal half-lives have been 
determined: 480 hours for risedronate, 146 hours for zoledronate and an estimate of over 
10 years for alendronate (Terveysportti: Lääkkeet ja hinnat 2015). For etidronate, 165 
days has been determined in animal studies (Genpharm Inc. 2006), while for clodronate 
an excact terminal half-life has not been established, other than the fact that it is very long 
(Castrén-Kortekangas et al. 1997). 
4.4 Bisphosphonates in periodontitis 
Bisphosphonates have been tested in humans and in animals against naturally occurring 
periodontitis. They have also been widely tested against experimentally induced 
periodontitis in animals (Goya et al. 2006). The experimental periodontitis is caused e.g. 
by a ligature around a tooth. It has been proved in previous studies that systemic 
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administration of bisphosphonates is effective in periodontitis, e.g. alendronate in beagle 
dogs (Reddy et al. 1995), alendronate in monkeys (Brunsvold et al. 1992; Weinreb et al. 
1994), alendronate in humans (Rocha et al. 2001; El-Shinnawi and El-Tantawy 2003; 
Rocha et al. 2004; Jeffcoat et al. 2007), alendronate in rats (Menezes et al. 2005; Moreira 
et al. 2014), clodronate in rats (Alencar et al. 2002), etidronate in humans (Takaishi et al. 
2001; Takaishi et al. 2003), risedronate in rats (Shoji et al. 1995) and risedronate in 
humans (Palomo et al. 2005). Because of the local nature of periodontitis, it would be 
justifiable to prefer local treatment, minimizing systemic effects (Mitsuta et al. 2002).  
Topically administered bisphosphonates have been tested in the treatment of periodontitis 
in humans and rats. Improved periodontal parameters (increased alveolar bone and/or 
attachment tissue levels) were demonstrated upon application of alendronate in the 
treatment of patients with chronic periodontitis (Veena and Prasad 2010; Sharma and 
Pradeep 2012a), aggressive periodontitis (Sharma and Pradeep 2012b), chronic 
periodontitis together with type 2 diabetes mellitus (Pradeep et al. 2012), bone resorptive 
lesions (Reddy et al. 2005) and experimental periodontitis in rats (Binderman et al. 2000; 
Yaffe et al. 2000). Improved bone parameters were also registered with clodronate in rats 
(Mitsuta et al. 2002; Liu et al. 2004), risedronate in rats (Adachi et al. 1994; Igarashi et 
al. 1996), olpadronate in rats (Goya et al. 2006) and tiludronate in rats (Furlaneto et al. 
2014). 
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5 BIOACTIVE GLASS 
5.1 Definition 
Bioactive glasses are synthetic silica-based bioactive materials with different 
compositions used as bone graft substitutes (Välimäki and Aro 2006). The first bioactive 
glass was 45S5 Bioglass® developed by Larry Hench in the 1960s (Hench 2006). 
Bioactive glass S53P4 (BAG), used in this thesis, is a III class medical device of BonAlive 
Biomaterials Ltd. (BonAlive® Biomaterials Ltd. 2015). Its composition by weight is: 
SiO2 53%, Na2O 23%, CaO 20%, P2O5 4%. BAG is indicated in the treatment of bone 
defects (Figure 8) caused by bone tumors, trauma and chronic infections, e.g. 
osteomyelitis and chronic sinusitis. It has osteoconductive (BonAlive® Biomaterials Ltd. 
2014), osteoproductive (Virolainen et al. 1997) and antibacterial properties (Stoor et al. 
1998; Leppäranta et al. 2008; Munukka et al. 2008; Drago et al. 2013; Coraça-Huber et 
al. 2014; Drago et al. 2014; Gergely et al. 2014; Romanò et al. 2014). Osteoproduction 
refers to the ability to promote migration, replication and differentiation of osteogenic 
cells and bone matrix production (Virolainen et al. 1997). In contrast, osteoconductivity 
facilitates new bone growth on and between the BAG granules (BonAlive® Biomaterials 
Ltd. 2015). 
 
Figure 8. BAG granules can be used to fill bone cavities. (BonAlive® Biomaterials Ltd. 
2015).  
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BAG is activated in aqueous solutions (BonAlive® Biomaterials Ltd. 2014). Clinical 
applications utilize sterile physiological saline. Ions (Ca2+, Na+, PO4(3-) and Si4+) are 
released into the surrounding fluid (Stoor et al. 1998). A silica-gel layer is formed on the 
glass surface (BonAlive® Biomaterials Ltd. 2014). The silica gel is formed by 
polycondensation of hydrated silica groups. This works as a platform for 
calciumphosphate precipitation. The calciumphosphate crystallizes to a hydroxyapatite 
surface, which bonds to bone. This hydroxyapatite resembles the mineral phase of natural 
bone, resorbs slowly and is replaced by natural bone over several years. The slow 
dissolution of BAG allows the natural bone to regenerate properly. 
5.2 Antibacterial properties of bioactive glasses 
BAG is known to have antibacterial (Stoor et al. 1998; Leppäranta et al. 2008; Munukka 
et al. 2008; Drago et al. 2013; Coraça-Huber et al. 2014; Gergely et al. 2014; Romanò et 
al. 2014) and anti-biofilm effects (Coraça-Huber et al. 2014; Drago et al. 2014). Because 
of this ability, its use is beneficial in the treatment of osteomyelitis (Romanò et al. 2014) 
and in chronic frontal sinusitis (Peltola et al. 2006). The antibacterial properties of 
bioactive glasses are thought to have several possible root causes. 
One antibacterial mechanism theory suggests that high calcium or alkali concentrations 
cause a disturbance of the bacterial membrane potential (Munukka et al. 2008). However, 
a more frequently suggested antibacterial mechanism involves elevated pH and osmotic 
pressure (Gubler et al. 2008). High pH and osmotic pressure are considered unfavorable 
for bacterial adhesion and proliferation, reducing infection occurrence possibility (Drago 
et al. 2014). BAG releases ions (Ca2+, Na+, PO4(3-) and Si4+) when in contact with an 
aqueous solution (Stoor et al. 1998). In the first phase, sodium ions are released from the 
bioactive glass surface, inducing pH elevation via NaOH formation (Gubler et al. 2008). 
With a slower onset, ions (remaining Ca2+, Na+, PO4(3-) and Si4+) are released sustainably 
(Gubler et al. 2008) increasing osmotic pressure (Munukka et al. 2008). According to 
Zhang et al. (2008) and Rosenqvist et al. (2014), elevation of pH is increased when the 
bioactive glass particle size is decreased, due to increased surface area per volume. 
Sodium-containing bioactive glasses have faster bactericidic effects than sodium-free 
glasses (Gubler et al. 2008). The antibacterial effect of BAG has been investigated widely 
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against many microbial species, whereas anti-biofilm effects have received less attention. 
The following paragraphs only deal with the microorganisms that are relevant from the 
perspective of this thesis. 
Stoor et al. (1996 and 1998) have investigated the antibacterial effect of BAG against 
planktonic A. actinomycetemcomitans. In their experiment (1998) they used 1667 mg/mL 
BAG (particle size ≤ 45 µm), which led to the bacteria losing their viability within one 
hour. In another study (1996), they evaluated the antibacterial effects of BAG discs on A. 
actinomycetemcomitans. The BAG discs were placed on agars right after microbe plating 
and no growth inhibition was observed. Interestingly, another study (Waltimo et al. 2006) 
found that the antibacterial efficacy of BAG against A. actinomycetemcomitans could be 
boosted by pre-culturing the bacteria with bone powder. With hydroxyapatite or 
decalcified bone powder, a similar boost was not noted. Furthermore, they hypothesized 
that the mineralized collagen of regular bone powder may act as a catalyst for BAG 
dissolution into a solvent, thus increasing pH and osmolarity. 
BAG has been tested against planktonic- and biofilm cultures of S. aureus using different 
BAG concentrations and particle sizes. Drago et al. (2013) tested concentrations of 400 
and 800 mg/mL (particle size 500–800 µm) against planktonic MRSA, and detected 
bacteria to lose viability within 72 hours with both concentrations. In addition, Drago et 
al. (2014) tested three BAG formulations against MRSA biofilms grown on titanium 
discs. The tested formulations were putty, powder (particle size ≤ 45 µm) and granules 
(particle size 500–800 µm) with concentrations of 400 mg/mL. BAG significantly 
reduced biofilm biomass while the tested formulations did not show marked efficacy 
differences. Coraça-Huber et al. (2014) compared the effectiveness of two different BAG 
particle sizes (≤ 45 µm and 500–800 µm) against planktonic S. aureus and S. aureus 
biofilms grown on titanium discs, with concentrations 250 mg/mL and 1000 mg/mL, 
respectively. They observed that samples of particle size ≤ 45 µm were more effective 
against planktonic cells and biofilms than the larger size of 500–800 µm. Furthermore, 
pH elevation was faster for the smaller particle size. They suggest that the smaller particle 
size is more active due to increased surface area per volume. Increased surface area leads 
to increased contact between the BAG and the aqueous environment, which indicates a 
greater release of the ions (Zhang et al. 2008). 
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In some studies, BAG has been compared to other bioactive glasses or materials from the 
antimicrobial perspective. Leppäranta et al. (2008) and Munukka et al. (2008) compared 
BAG (particle size ≤ 45 µm) to other bioactive glasses. They screened several clinically 
relevant planktonic anaerobic (Leppäranta et al. 2008) and aerobic (Munukka et al. 2008) 
bacterial strains and observed that BAG was the most effective out of the tested bioactive 
glasses: it effectively inhibited the growth of even the most resistant pathogens. BAG also 
inhibited bacterial growth with lower concentrations than any other bioactive glass. 
Finally, Gergely et al. (2014) compared the antibacterial effect of BAG and an antibiotic, 
gentamicin. Gentamicin was embedded in polymethylmethacrylate beads. These beads 
were used in the experiment because they act as a current “gold standard” treatment of 
osteomyelitis, in combination with the appropriate impregnated antibiotic. However, they 
are not biodegradable, so another surgery is required for their removal. In contrast, 
removal is not necessary for biodegradable bioactive glass. They used BAG as granules 
(2.0–3.15 mm diameter) and in powdered form. Planktonic S. aureus was one of the tested 
strains, and there was no significant difference between BAG and the beads. In contrast, 
other tested strains were more susceptible to the gentamicin-containing beads than BAG. 
5.3 Bioactive glasses in periodontitis 
The applicability of bioactive glasses has been expanded to dentistry, e.g. to treat 
hypersensitive teeth (Forsback et al. 2004; Tirapelli et al. 2011). In other dental 
applications, bioactive glasses are interesting due to their ability to mineralize dentine 
(Forsback et al. 2004) and to function as an antimicrobial agent (Stoor et al. 1998). 
Bioactive glasses can be used in the treatment of periodontitis as a bone-augmenting 
agent, as well (Stoor et al. 1996). Improved periodontal parameters (increased attachment 
and alveolar bone levels) in humans have been gained with the 45S5-bioactive glass 
(Mengel et al. 2003; Mengel et al. 2006) and with its granulated form, PerioGlas® 
(Chacko et al. 2014). PerioGlas® is in clinical use for treatment of oral or dental osseous 
defects (NovaBone Products 2015). 
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5.4 Combination of bioactive glass and bisphosphonates 
The last decade has seen an emergent interest towards bioactive glass combination 
products (Rosenqvist et al. 2013). One research topic focuses on bioactive glass bone 
growth ability enhancement with other compounds, such as bisphosphonates. Srisubut et 
al. (2007) have presented promising results in rats by combining these two components. 
In their study, local administration of alendronate-bioactive glass combination indicated 
significantly higher bone formation than bioactive glass administered alone. Local 
clodronate-BAG has also been tested in patients with periodontitis (Rosenqvist K, 
unpublished observation 2014). For each patient, two periodontal pockets were treated: 
one with the combination and the other with solely BAG. The amounts and grades of the 
combination ingredients were based on their earlier study, where they compared 100, 200 
and 300 mg of clodronate combined with 1 gram of different particle sizes of bioactive 
glass (Rosenqvist et al. 2014). They chose 200 mg of clodronate and 1 gram BAG with 
particle size 500–800 µm for their further studies. This combination decreased the 
sensitivity symptoms of the patients slightly more than BAG alone (Rosenqvist K, 
unpublished observation 2014). Correspondingly, in their earlier study (Rosenqvist et al. 
2014), pH increase of solely bioactive glass was more radical than the clodronate-BAG-
combination. During physicochemical property characterization, it was observed that a 
combination product of clodronate-BAG enhanced bioactivity via longer-lasting and 
more extensive ion exchange, compared to BAG (Rosenqvist et al. 2013). Conversely, if 
excessive calcium clodronate is precipitated due to a large amount of clodronate, the 
hydroxyapatite formation of BAG is decreased (Rosenqvist et al. 2014). As a result, 
dental applications require that the amount of clodronate is sufficient for ion exchange 
enhancement, but not excessive so that hydroxyapatite formation is retained. 
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6 AIMS OF THE STUDY 
The experimental part of the thesis is divided into three parts. Anti-biofilm effects of 5 
bisphophonates (alendronate, clodronate, etidronate, risedronate and zoledronate) were 
investigated 1) alone in solution and 2) together with bioactive glass, i.e. as a part of the 
combination product. In addition, 3) pH measurements were included to examine a 
possible anti-biofilm mechanism of bisphosphonates and bisphosphonate-BAG 
combinations. 
The aim of the first part was to clarify if bisphosphonates have intrinsic effects against 
biofilms. This was investigated with pre- and post-exposure tests performed in 96-well 
plates. The second part investigated whether a bisphosphonate-bioactive glass 
combination has better anti-biofilm effects compared to bioactive glass alone. Here, the 
Static Biofilm method was utilized. The periodontopathogen Aggregatibacter 
actinomycetemcomitans ATCC 33384 was chosen for both of these anti-biofilm 
experiments, while Staphylococcus aureus Newman was tested only in the first part for 
assay optimization. During the first two parts, optimization of experimental methods in 
the study of A. actinomycetemcomitans ATCC 33384 was performed. According to the 
best knowledge of the author, bioactive glass has not been investigated against A. 
actinomycetecomitans biofilms. The purpose of the third part was to establish, whether 
potential anti-biofilm effects are connected with a significant alteration in acidity or 
basicity through a clinically relevant period of exposure.  
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7 MATERIALS AND METHODS 
7.1. Materials and bacterial strains 
7.1.1 Materials 
Tryptic soy agar (TSA; Lot. BCBM4691V and BCBJ5358V), tryptic soy broth (TSB; 
Lot. BCBM6802V), dextrose (Lot. 031M0140V), Tween® 20 (Lot. SZBE0630V), 
resazurin sodium salt (molecular weight (MW) = 251.14 g/mol; Lot. MKBL3135V), 
crystal violet solution (2.3% weight/volume (w/v); Lot. 091M4364), rifampicin (MW = 
822.94 g/mol; Lot. SLBH2676V), penicillin G sodium salt (MW = 356.37 g/mol; Lot. 
BCBB8234V), chlorhexidine dihydrochloride (MW = 578.37 g/mol; Lot. BCBN2790V), 
etidronic acid monohydrate (Table 5; Lot. BCBC7777V) and sodium chloride ACS (Lot. 
109K0076) were purchased from Sigma-Aldrich (Steinheim, Germany). Alendronate 
sodium trihydrate (Table 5; Lot. 1029/P/02001) and zoledronic acid monohydrate (Table 
5; Lot. 120822) were acquired from Kemprotec Limited (Carnforth, United Kingdom). 
Risedronic acid monohydrate (Table 5; Lot. LC24373) was from AK Scientific (Union 
City, California, USA), while clodronate disodium tetrahydrate (Table 5; Lot. T07/009 
Ph. Eur.) was obtained from PharmaZell GmbH (Raubling, Germany). BactoTM Yeast 
Extract (Lot. 8231161) was produced by Becton, Dickinson and Company (Le Pont de 
Claix, France). Bioactive glass S53P4 (BAG; granule size: 500–800 µm; Lot. BG-05/13 
and BS-16/13/9) was purchased from BonAlive Biomaterials Ltd. (Turku, Finland). 
Aseptically collected defibrinated sheep blood was purchased from Bio Trading (Lot. 
14297 SG85, 14325 SG93 and 15009 SG21). LIVE/DEAD® BacLightTM Bacterial 
Viability Kit L7007 (Lot. 1562297) was from Molecular Probes by Life Technologies 
(Eugene, Oregon, USA). Phosphate buffered saline (PBS; Lot. 4MB127) was from Lonza 
(Verviers, Belgium). Sodium hypochlorite (14% Cl2 in aqueous solution; Lot. 
14G100514) was from VWR Chemicals (Fontenay-sous-Bois, France). Etax Aa 
(minimum 99.5 weight-%; Lot. 13202) was from Altia Oyj (Rajamäki, Finland).  
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Table 5. The bisphosphonates used in the experiments. The purities of all five 
bisphosphonates were ≥ 95%. 
Bisphosphonate CAS 
Molecular 
formula 
Molecular 
weight 
Alendronate sodium trihydrate 
121268- 
17-5 
C4H12NNaO7P2 ·  
3 H2O 
325.12 g/mol 
Clodronate disodium tetrahydrate 
22560- 
50-5 
CH2Cl2 Na2O6P2 · 
4 H2O 
360.92 g/mol 
Etidronic acid monohydrate 
25211- 
86-3 
C2H8O7P2 ·  
H2O 
224.04 g/mol 
Risedronic acid monohydrate 
105462- 
24-6 
C7H11NO7P2 ·  
H2O 
301.13 g/mol 
Zoledronic acid monohydrate 
165800- 
06-6 
C5H10N2O7P2· 
H2O 
290.10 g/mol 
 
7.1.2 Bacterial strains 
The strain Aggregatibacter actinomycetemcomitans ATCC (American Type Culture 
Collection) 33384 was kindly donated by Dr. Pirkko Pussinen from the Institute of 
Dentistry, University of Helsinki, Finland. Staphylococcus aureus Newman was similarly 
donated by Docent Pekka Varmanen from the Faculty of Veterinary Medicine, University 
of Helsinki, Finland. 
7.2 Biofilm trials performed in 96-well plates 
Anti-biofilm effects of bisphosphonates as stand-alone compounds were first investigated 
in susceptibility trials. The trials were performed in 96-well plates, which is one of the 
most widely used systems for quick assessment of anti-biofilm activity in a convenient-
to-use format. Tested compounds included five bisphosphonates: alendronate, clodronate, 
etidronate, risedronate and zoledronate.  
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7.2.1 Bacterial culturing and biofilm formation by Staphylococcus aureus Newman 
The strain Staphylococcus aureus Newman was stored on a TSA plate at a temperature 
of 4°C. Pre-cultures were initiated by taking a full 1 µl-loop of colonies from the TSA 
plate (less than 1 month old) and transferring them into a Falcon tube containing 3 
milliliters of TSB. The pre-cultures were incubated under aerobic conditions at 37°C with 
200 rpm shaking for 12–16 hours (Skogman et al. 2012). Liquid cultures were prepared 
by diluting the pre-cultures 1:1000 in TSB and incubated under aerobic conditions at 
37°C with 200 rpm shaking for 3–5 hours to reach an exponential growth (usually a 
concentration of 108 CFU• mL-1). The bacterial concentration was estimated with 
VarioskanTM Flash Multimode Reader (Thermo Fisher Scientific Inc., Waltham, 
Massachusetts, USA) by measuring spectrophotometric turbidity at 595 nm. A 
spectrophotometer passes light through a cell suspension and measures unscattered light 
(Tortora et al. 2014c). Turbidity i.e. optical density increases when more cells are present 
in the cell suspension. The bacterial concentration was then confirmed via determination 
of viable colony forming units per milliliter (CFU• mL-1) by performing 10-fold serial 
dilutions in TSB. Four sequential dilutions (5 drops, à 10 µl) were plated onto quarters of 
TSA on a Petri dish (VWR, Radnor, Pennsylvania, USA). TSA plates were incubated 
under aerobic conditions at 37°C for 16–18 hours. After incubation, the plate count was 
perfomed, where viable colony forming units (CFU) were determined. The concentration 
(CFU• mL-1) was calculated according to Equation 1 (Tortora et al. 2014c). 
𝐶𝐹𝑈 •  𝑚𝐿−1 =  
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑜𝑓 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑐𝑜𝑙𝑜𝑛𝑖𝑒𝑠 𝑥 
1
𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛
𝑉𝑜𝑙𝑢𝑚𝑒 𝑝𝑙𝑎𝑡𝑒𝑑 (𝑚𝐿)
                (1) 
For forming biofilms, the exponentially grown cultures were diluted 1:100 in TSB in 
order to contain approximately 106 CFU• mL-1. Biofilms were grown on sterile, flat-
bottomed Nunclon™ Δ surface 96-well polystyrene plates (NuncTM, Roskilde, Denmark).  
7.2.2 Bacterial culturing and biofilm formation by Aggregatibacter 
actinomycetemcomitans ATCC 33384 
The strain of Aggregatibacter actinomycetemcomitans ATCC 33384 was stored at a 
temperature of -80°C in milk. The strain was recovered by spreading 20 µl of the bacterial 
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stock suspension onto a TSA plate supplemented with 5% defibrinated sheep blood 
(TSAD5) (Paino et al. 2011). The plates were incubated in microaerophilic conditions at 
37°C for 3 days. These microaerophilic conditions were accomplished by maintaining the 
bacteria in an airtight container with a candle inside (“candle jar”). This ensemble 
typically provides conditions that are known to be favorable for the growth of this 
microorganism (Paino et al. 2011): richer with carbon dioxide (3%) and lower with 
oxygen (17%) than in the atmosphere (Tortora et al. 2014c).  
After the bacterial colonies had clearly formed on the plates under the conditions 
described above, 4 full 1 µl-loops of colonies from the plate were scraped into 1 mL of 
TSB-YE/Glc (TSB supplemented with 0.6% (w/v) yeast extract and 0.8% (w/v) glucose) 
(Paino et al. 2011) to gain an optical density of 1 (approximately 109 CFU• mL-1). The 
optical density values were measured with VarioskanTM Flash Multimode Reader at 595 
nm and confirmed by determining viable CFU• mL-1 (see 7.2.1.) on TSAD5. Serial 
dilutions were performed with TSB-YE/Glc (Figure 9). The plates were incubated in 
microaerophilic conditions at 37°C for 3 days. 
 
Figure 9. A. actinomycetemcomitans ATCC 33384 grown on TSAD5 plate using 4 serial 
dilutions for CFU• mL-1 determination. 
 
For biofilm formation, the exponentially grown cultures were diluted 1:100 with TSB-
YE/Glc to be approximately 107 CFU• mL-1. Biofilms were grown on sterile, flat-
bottomed polystyrene 96-well plates.  
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The suitable A. actinomycetemcomitans ATCC 33384 biofilm formation time was 
determined by growing biofilms 24 and 48 hours at 37°C in microaerophilic conditions. 
The formed biofilms were stained with crystal violet. Planktonic suspension was removed 
and rinsed with 200 µl of Milli-Q-water (Sandberg et al. 2008). Then, 170 µl of crystal 
violet stain (2.3% w/v) was added and allowed to stain for 5 minutes at room temperature 
(RT) and removed. The Milli-Q-water washing step was perfomed another two times. 
The remaining dye was solubilized in 200 µl of 96% ethanol for one hour (at RT). 
Absorbance was measured at 595 nm using VarioskanTM Flash Multimode Reader.  
7.2.3. Exposure of biofilms to the tested compounds or control antibiotics 
Bisphosphonates, penicillin G and rifampicin were dissolved in water in stock solutions 
of 3 mM, 4 mM and 100 µM, respectively. However, taking into account the diluting 
effect of the bacterial suspension (180 µl), the final concentrations of the compound 
solution (20 µl) encountered by bacteria were 10-fold smaller. Thus, final concentrations 
for the tested compounds were 300 µM, 400 µM and 10 µM, respectively. The antibiotics 
penicillin G and rifampicin served as positive controls for S. aureus Newman and A. 
actinomycetemcomitans ATCC 33384, respectively.  
The tested compounds were measured in two different modes: pre- and post-exposure. 
The workflows are presented in Figure 10 (for S. aureus Newman) and in Figure 11 (for 
A. actinomycetemcomitans ATCC 33384). In the pre-exposure assay, 20 µl of compounds 
were dispensed at the same time with 180 µl of bacterial suspensions (106 CFU• mL-1 for 
S. aureus Newman and 107 CFU• mL-1 for A. actinomycetemcomitans ATCC 33384). The 
plates were incubated under aerobic conditions at 37 °C, with 200 rpm for 18 hours (S. 
aureus Newman) (Skogman et al. 2012) or in microaerophilic conditions at 37 °C for 24 
hours (A. actinomycetemcomitans ATCC 33384). In the post-exposure assay, 200 µl of 
bacterial suspension was added per well (106 CFU• mL-1 for S. aureus Newman and 107 
CFU• mL-1 for A. actinomycetemcomitans ATCC 33384), and biofilms were first allowed 
to form for 18 hours (S. aureus Newman) (Skogman et al. 2012) or 24 hours (A. 
actinomycetemcomitans ATCC 33384). After this incubation period, planktonic 
suspension was removed (Skogman et al. 2012). 20 µl of compound and 180 µl of TSB 
(S. aureus Newman) or 180 µl TSB-YE/Glc (A. actinomycetemcomitans ATCC 33384) 
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were then pipetted onto the formed biofilms and allowed to have an effect on the biofilms 
for an additional 24 hours. 
 
Figure 10. The workflow for testing non-active (NA) and active compound (A) against S. 
aureus Newman (modified from Skogman et al. 2012). A yellow star indicates 
fluorescence. 
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Figure 11. The workflow for testing non-active (NA) and active compound (A) against 
A. actinomycetemcomitans ATCC 33384 (modified from Skogman et al. 2012). A yellow 
star indicates fluorescence. 
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7.2.4 Quantification of biofilm viability 
After exposure to the compounds or control antibiotics, viable biofilms were stained. 
First, planktonic suspension was removed. Then, biofilms were stained with 200 µl of 20 
µM resazurin in PBS. The incubation time of S. aureus Newman (Figure 12) was 20 
minutes (at RT, 200 rpm, in the darkness). The concentration of resazurin solution and 
the incubation time were based on Sandberg et al. (2009). For A. actinomycetemcomitans 
ATCC 33384, the same concentration of resazurin was used, but the incubation time was 
chosen to be 60 minutes in microaerophilic conditions (at RT, in the darkness), based 
upon optimization. In optimization trials, different incubation times and conditions were 
compared. The incubation was first performed in aerobic conditions (at RT, in the 
darkness) (45, 60, 85, 120 and 240 minutes).  After that, incubation was performed in 
microaerophilic conditions (at RT, in the darkness) (60 minutes). Fluorescence caused by 
resazurin reduction was monitored by utilizing excitation and emission wavelengths of 
560 and 590 nm, respectively. Measurements were made using the VarioskanTM Flash 
Multimode Reader.  
 
Figure 12. Resazurin stained S. aureus Newman on 96-well plates. The compound plates 
above and the control plates (no compounds added) below. The blue color indicates 
medium or non-bacterial metabolic activity and the pink color indicates bacterial 
metabolic activity.  
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Performance of screening assays can be estimated by means of statistical parameters. 
These include a signal window coefficient (Z’-factor; Equation 2) (Zhang et al. 1999), 
signal-to-noise ratio (S/N; Equation 3) (Sandberg et al. 2008) and signal-to-background 
ratio (S/B; Equation 4) (Zhang et al. 1999). The active compound can be distinguished 
from non-active compounds in well plate assays with the aid of a threshold value (hit 
limit; HL; Equation 5) (Zhang et al. 1999). 
SDmin and SDmax indicate standard deviations of minimal signal and maximal signal, 
respectively. Xmin and Xmax describe the mean of the minimal signal and maximal signal, 
respectively. The maximal signal is the signal of positive control wells including only 
bacterial suspension, while the minimal signal is the signal given by negative control 
wells, which include only medium.  
𝑍′ = 1 −  
(3 𝑥 𝑆𝐷𝑚𝑎𝑥 + 3 𝑥 𝑆𝐷𝑚𝑖𝑛)
|𝑋𝑚𝑎𝑥 − 𝑋𝑚𝑖𝑛|
                                         (2) 
 
𝑆
𝑁
=
𝑋𝑚𝑎𝑥 − 𝑋𝑚𝑖𝑛
(𝑆𝐷𝑚𝑎𝑥
2 +  𝑆𝐷𝑚𝑖𝑛
2)1/2
                                               (3) 
 
𝑆
𝐵
=  
𝑋𝑚𝑎𝑥
𝑋𝑚𝑖𝑛
                                                               (4) 
 
𝐻𝐿 = 𝑋𝑚𝑎𝑥 − 3 × 𝑆𝐷𝑚𝑎𝑥                                                   (5) 
7.2.5 Quantification of biofilm biomass 
After resazurin staining, A. actinomycetemcomitans ATCC 33384 biofilms were also 
stained with crystal violet, since this method had earlier been reported as typical for 
biomass quantification of biofilms (Sandberg et al. 2008). In addition, this was a useful 
strategy to confirm feasibility of the performed redox staining (resazurin). The resazurin 
stain was removed and rinsed with 200 µl of Milli-Q-water. Then, 170 µl of crystal violet 
stain (2.3% w/v) was added and allowed to stain for 5 minutes at RT and removed. The 
Milli-Q-water washing step was perfomed another two times. The remaining dye was 
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solubilized in 200 µl of 96% ethanol for one hour (at RT). Absorbance was measured at 
595 nm using VarioskanTM Flash Multimode Reader.  
7.3 Biofilm trials performed with the Static Biofilm method  
The combinations of bioactive glass and bisphosphonates were investigated in a dental 
biofilm model, using the Static Biofilm method as described in Oja et al. (2014). This 
method was chosen because of its ability to mimic oral conditions. In practice, this 
requires the absence of fluid shear stress and a small fluid volume. The same 
bisphosphonates were included as in previous experiments: alendronate, clodronate, 
etidronate, risedronate and zoledronate. Inert glass beads served as a negative control. In 
the Static Biofilm method, biofilms typically develop on the underside surfaces of 
coupons which are placed on a filter paper covered agar (Charaf et al. 1999; Oja et al. 
2014). The protocol was modified from Oja et al. (2014) in three specific points: 1) a 
second layer of filter paper was added in susceptibility trials, 2) the filter papers were 
remoistened with undiluted medium in susceptibility and optimization trials, 3) for 
practical reasons, compound covered coupons were not immersed into the medium prior 
to sonication in susceptibility trials, as detailed below. The main steps of the Static 
Biofilm method are presented in Figure 13.  
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Figure 13. Workflow of the Static Biofilm method utilized in this investigation. Biofilms 
are drawn in yellow (modified from Oja et al. 2014). 
 
In the publication of Oja et al. (2014) only glass coupons were used. In contrast, the 
present study also experimented with other materials that were more relevant for the 
dental application. This was based on an optimization study, which is described in 
subsection 7.3.2. 
7.3.1 Cleaning of coupons used as surfaces  
Cleaning of coupons was performed twice, right before and after their usage. The cleaning 
was performed according to an ASTM protocol (ASTM International Standard E2196-
12), but sodium hypochlorite treatments were added to avoid contamination, as described 
below. 
Before use, coupons were soaked for 30 minutes in 14% sodium hypochlorite. This was 
followed by a 10 minute sonication in 70% ethanol in a water bath. Finally, coupons were 
soaked in Etax Aa and dried in a laminar hood.  
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After use, coupons were visually inspected for damages. After that, they were sonicated 
for 30 seconds in a 1% SDS-water solution. SDS (sodium lauryl sulphate) is a tencide. 
Then, the coupons were rinsed with MQ-water until no bubbles were present and 
sonicated in MQ-water for 5 minutes. The coupons were rinsed a further three times with 
MQ-water. Next, coupons were soaked for 30 minutes in 14% sodium hypochlorite to 
ensure full eradication of the remaining biofilms. Before storing, coupons were briefly 
dipped into Etax Aa to rinse the sodium hypochlorite and let to dry in a laminar hood. 
7.3.2 Coupon optimization 
Before proceeding to susceptibility trials performed with the Static Biofilm method, 
suitable materials for biofilm formation were assessed. In this optimization study, glass, 
plexi glass and hydroxyapatite coupons were compared without any samples to clarify 
how A. actinomycetemcomitans ATCC 33384 bacteria attach onto different materials. 
The purpose was to determine whether hydroxyapatite or plexi glass coupons (more 
relevant for dental application) could be used instead of glass coupons, which were used 
in Oja et al. (2014). Hydroxyapatite [Ca10(PO4)6(OH)2] is the mineral component of 
dentine and bones (Pryor et al. 2009), and both hydroxyapatite and plexi glass are used 
as materials in dental implants. Thus, a quick comparative screen of A. 
actinomycetemcomitans ATCC 33384 attachment on 3 different coupon materials 
(hydroxyapatite, plexi glass, glass) were studied.  
The pre-culture of A. actinomycetemcomitans ATCC 33384 was prepared as previously 
described in subsection 7.2.2. A sterile Whatman filter paper (70 mm diameter, 
Qualitative Grade 2, GE Healthcare, Little Chalfont, United Kingdom) was placed on a 
TSAD5 plate (Oja et al. 2014). The filter paper was inoculated with 1.5 mL of 10
7 CFU• 
mL-1 pre-culture dilution. The sterile coupons [borosilicate glass (0.4 cm height, 1.27 cm 
diameter), plexiglass (acrylic; 0.4 cm height, 1.27 cm diameter) and hydroxyapatite (0.25 
cm height, 1.27 cm diameter), BioSurface Technologies Corporation, Montana, USA] 
without compound samples were placed on this paper. The plate was incubated at 37°C 
for 48 hours under humidified microaerophilic conditions. After 24 hours of incubation, 
the filter paper was remoistened with 1.5 mL of undiluted TSB-YE/Glc. The coupons 
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were immersed into medium to remove planktonic suspension, and sonication for the 
biofilm quantification phase (7.3.5) was performed. 
7.3.3 Preparation of the tested samples 
The combination samples were formed by mixing 50 mg of bisphosphonate or inert glass 
beads (Figure 14) and 500 mg of BAG and 450 µl of saline 0.9% (w/v) for each coupon, 
in the same manner as performed by Rosenqvist et al. (2014). Each prepared sample was 
then transferred to a filter paper in order to evaporate excessive saline. The coupons were 
covered with the samples using a spatula. Furthermore, suitability of inert glass beads 
(Jencons Ltd., Bedfordshire, UK) as a negative control material was evaluated by 
combining 550 mg of the beads with 450 µl of saline. 
 
Figure 14. Flashsizer image of inert glass beads used as a negative control in the Static 
Biofilm method. 
 
7.3.4 Bacterial culturing and biofilm formation by Aggregatibacter 
actinomycetemcomitans ATCC 33384 
The pre-culture of A. actinomycetemcomitans ATCC 33384 was prepared as previously 
described in subsection 7.2.2. A sterile filter paper (70 mm diameter) was placed on 
TSAD5 plates (Oja et al. 2014). Smaller sterile filter papers per each coupon (25 mm 
diameter, cut from 70 mm diameter) were placed on the larger ones. The function of the 
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large filter paper was to prevent coupons from sticking to the agar and to act as a barrier 
material, enabling nutrients to diffuse from the agar to the coupon surface (Oja et al. 
2014). The purpose of the smaller filter paper was to facilitate the scraping of samples 
into Falcon tubes in the later biofilm disaggregation phase. The double-layered filter 
papers were inoculated with 1.5 milliliter of 107 CFU• mL-1 pre-culture dilution (Oja et 
al. 2014). The sterile coupons covered with a sample were placed on the smaller filter 
papers, so that the samples lie between the coupons and the smaller filter papers (Figure 
15). The biofilms develop on the filter papers, on the samples and on the underside of the 
coupons. The plates were incubated at 37°C for 48 hours under humidified 
microaerophilic conditions. After 24 hours of incubation, the filter paper was remoistened 
with 1.5 mL of undiluted TSB-YE/Glc. 
 
Figure 15. The Static Biofilm method using A. actinomycetemcomitans ATCC 33384. 
  
7.3.5 Quantification of biofilms 
After 48 hours of incubation, the coupons and samples were transferred into Falcon tubes 
containing 1 mL of 0.5% (w/v) Tween® 20 in TSB-YE/Glc, as in Oja et al. (2014). The 
tubes were sonicated in Ultrasonic Cleaner 3800 (Branson Ultrasonics, Danbury, 
Connecticut, USA) in a water bath for 5 minutes at 25°C, 35 kHz. A 20 second vigorous 
mixing of the tubes was performed with Vortex mixer SA8 (Stuart, Stone, United 
Kingdom) just before and after sonication. Serial dilutions of the resulting suspensions 
were prepared and plated onto TSAD5 plates to determine viable colony forming units per 
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milliliter (CFU• mL-1) as described in the subsection 7.2.1. The plates were incubated 
under microaerophilic conditions at 37°C for 3 days. The bacterial attachment on coupons 
is expressed on a log10 scale, and compound anti-bacterial effects can be expressed as 
logarithmic Reduction of the bacterial burden (logR-values, Equation 7) (Buckingham-
Meyer et al. 2007).  
 
𝑙𝑜𝑔𝑅 = 𝑙𝑜𝑔10〈(𝐶𝐹𝑈/𝑚𝑙)𝑐𝑜𝑛𝑡𝑟𝑜𝑙〉 −  𝑙𝑜𝑔10〈(𝐶𝐹𝑈/𝑚𝑙)𝑐𝑜𝑚𝑝𝑜𝑢𝑛𝑑〉               (7) 
 
where 〈∙〉 denotes averaging over samples. 
7.4 Fluorescence microscopy 
7.4.1 Biofilm formation and exposure to compounds 
Bacterial culturing by A. actinomycetemcomitans ATCC 33384 was performed as 
previously described in subsection 7.2.2. The cultures were then diluted 1:100 to be 
approximately 107 CFU• mL-1 in TSB-YE/Glc to form biofilms. Round coverslips (13 
mm diameter, VWR International, Helsinki, Finland) were used as substrates for biofilm 
formation for the imaging. The coverslips were first cleaned by immersing them into 14% 
sodium hypochlorite, then into Etax Aa and finally into sterile water. After that, they were 
let to dry in a laminar hood. Biofilms were then grown onto the coverslips, which were 
placed on sterile, flat-bottomed Nunclon™ Δ surface 24-well polystyrene plates (NuncTM, 
Roskilde, Denmark). In treated wells, 100 µl of compound solution was dispensed 
simultaneously with 900 µl of bacterial suspension, while in untreated biofilms, 1000 µl 
of bacterial suspension was added. The biofilms were treated with 250 µM chlorhexidine 
and 100 µM rifampicin stock solutions, which were prepared by dissolving them into 
water. The final concentrations encountered by the bacteria were 25 µM and 10 µM, 
respectively. The plates were incubated in microaerophilic conditions at 37 °C for 24 
hours. 
As a parallel procedure, a 96-well plate pre-exposure test was performed to support data 
gained from FM. A. actinomycetemcomitans ATCC 33384 culturing, biofilm formation 
and biofilm exposure to the compounds were performed as described in the subsections 
 49   
 
7.2.2 and 7.2.3. Biofilms were exposed to the same antibiotics and concentrations as in 
the former paragraph, and incubated in microaerophilic conditions at 37 °C for 24 hours. 
Following the exposure, viable biofilms were stained. First, the planktonic suspension 
was removed. Then, biofilms were stained with 200 µl of 20 µM resazurin in PBS for 60 
minutes in microaerophilic conditions (at RT, in the darkness). Fluorescence caused by 
resazurin reduction was measured with VarioskanTM Flash Multimode Reader, using 
excitation and emission wavelengths of 560 and 590 nm, respectively. 
7.4.2 Staining of biofilms for fluorescence microscopy 
For fluorescence microscopy (FM) studies, bacteria were stained with fluorescent probes. 
In LIVE/DEAD® BacLight™ Bacterial Viability Kits, green-fluorescent nucleic acid 
probe SYTO® 9 and the red-fluorescent nucleic acid probe propidium iodide are 
combined (Molecular Probes 2004). The spectral characteristics and their ability to 
penetrate into healthy bacterial cells vary between these probes. The SYTO® 9 probe 
usually labels all bacteria in a population, with both intact and damaged membranes. 
Instead, propidium iodide can only penetrate into bacteria with damaged membranes, 
causing a reduction in the SYTO® 9 stain fluorescence when both dyes are present. Thus, 
bacteria with intact cell membranes are labeled fluorescent green, whereas bacteria with 
damaged membranes are labeled fluorescent red.  The excitation/emission maxima for 
these dyes are about 480/500 nm for SYTO® 9 and 490/635 nm for propidium iodide, 
when the background remains virtually nonfluorescent. 
After 24 hours of incubation (24-well plate), the planktonic suspension was removed. 
Biofilms were washed with saline (0.9% w/v) and stained with LIVE/DEAD® 
BacLightTM Bacterial Viability Kit L7007. The probe mixture was prepared by dissolving 
1.5 µL of Component A (1.67 mM SYTO® 9 nucleic acid stain and 1.67 mM propidium 
iodide in DMSO) and 1.5 µL of Component B (1.67 mM SYTO® 9 nucleic acid stain 
and 18.3 mM propidium iodide in DMSO) in 1 mL of sterile water. From this solution, 
34.5 µl was dispensed per well (final concentrations of SYTO® 9 and propidium iodide 
were 5 and 30 M, respectively). Biofilms were incubated with the probe solution at RT, 
in the darkness for 15 minutes. Next, the coverslips were carefully removed with tweezers 
and mounted with BacLightTM mounting oil on a Superfrost® Plus microscope glass slide 
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(25 x 75 x 1.0 mm, Thermo Scientific, Braunschweig, Germany) upside down. Images 
were acquired with a fluorescence microscope EVOS® FL Imaging System AMF4300 
(Life TechnologiesTM, Eugene, Oregon, USA) using two light cubes (RFP and GFP to 
detect the propidium iodide and SYTO® 9 emission, respectively), and a 40X (Inf Plan 
Fluor 40X, 0.75NA/0.72WD, coverslip corrected) objective. Images with the independent 
channels were captured and the one containing the overlay of both channels was 
automatically created by the microscope software.  
7.5 Particle size determination 
The particle sizes of bisphosphonates and inert glass beads were evaluated with Flashsizer 
FS3D (Intelligent Pharmaceutics Ltd., Helsinki, Finland), a 3D surface-imaging device 
(Soppela et al. 2011). It utilizes a technique where white light is illuminated from different 
angles to create 3D surfaces. This rapid technique can be used to determine particle sizes. 
In addition, the technique offers information regarding particle shape and roughness. A 
few cubic centimeters of compounds were transferred on a plate and measured. The 
particle sizes are expressed as D10-, D50- and D90-fractile values, meaning that 10%, 
50% and 90% of particles (respectively) are smaller than the presented size range. 
7.6 pH measurements 
For pH measurements, 300 µM bisphosphonate solutions in TSB and TSB-YE/Glc were 
prepared to mimic the conditions which S. aureus Newman and A. 
actinomycetemcomitans ATCC 33384 encountered in the 96-well plate test, respectively. 
To imitate the conditions in the Static Biofilm assay, 50 mg of bisphosphonate or inert 
glass beads, 500 mg of BAG and 450 µl saline were combined. As control, 550 mg of 
inert glass beads and 450 µl saline were mixed. pH values were measured at the following 
points in time: 0, 30, 60, 90, 120, 240, 360, 480 minutes, 24 hours, 48 hours and 72 hours. 
As an additional control, the values were also measured from media (TSB, TSB-YE/Glc 
and saline) at time points 0, 24, 48, 72 hours. The measurement apparatus 744 pH Meter 
Ω (Metrohm AG, Herisau, Switzerland) was calibrated daily. 
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7.7 Data processing and statistical analysis 
Data processing and statistical analysis was performed with Microsoft Excel 2013 
software and GraphPad Software (Prism, version 5.0 for Mac). For paired comparisons 
of the gathered data, an unpaired t-test with Welch’s correlation was utilized. p < 0.05 
was considered statistically significant.   
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8 RESULTS AND DISCUSSION 
On the market, there is a wide range of antimicrobial agents with proven efficacy against 
planktonic bacteria (Skogman 2012). However, no effective anti-biofilm agents are yet 
available for clinical use. This problem could be overcome with proper anti-biofilm 
testing. As presented in the subsection 2.6, there are five ASTM standardized methods 
for biofilm studies, but these methods are only optimized for the strain Pseudomonas 
aeruginosa. Thus, establishing anti-biofilm testing protocols could allow testing of 
antimicrobials already on the market, widening their indications. 
In this thesis, a focal topic was periodontal biofilms. They are treated with topically 
administered chlorhexidine and strain-specific antibiotics (Current Care Guidelines 
2010). However, these antimicrobials do not offer solutions for periodontal attachment 
tissue and alveolar bone loss. In this thesis, a therapeutical approach composed of 
bioactive glass and bisphosphonates is further investigated. These two compounds were 
combined, because it was hypothesized that this combination could simultaneously treat 
both the underlying root cause (biofilms) and consequences (alveolar bone and 
attachment tissue loss) of periodontitis. For bisphosphonates, other potential beneficial 
attributes considering periodontitis have also been presented. Some bisphosphonates are 
known to possess antimicrobial and anti-inflammatory effects in addition to their positive 
bone effects. This could potentially be beneficial considering periodontal treatment. 
Antimicrobial effects of clodronate against Pseudomonas aeruginosa, alendronate 
against P. aeruginosa, Candida albicans and Escherichia coli (Kruszewska et al. 2002), 
risedronate against P. aeruginosa and E. coli have been reported (Kruszewska et al. 
2012). Alendronate treatment in rat decreased periodontal pathogen levels in vivo 
(Menezes et al. 2005). In the treatment of inflammatory diseases such as periodontitis, 
the anti-inflammatory effect could be beneficial. It has been proved that clodronate has 
inflammation suppressing effects (Österman et al. 1995; Mönkkönen et al. 1998). In 
contrast, N-containing bisphosphonates have shown effects that are rather pro- than anti-
inflammatory (Mönkkönen et al. 1998; Makkonen et al. 1999; Pecherstorfer et al. 2000). 
The purpose of this work was to investigate anti-biofilm effects of bisphosphonates as 
stand-alone compounds and combined with bioactive glass. A late colonizer A. 
actinomycetemcomitans ATCC 33384 was chosen to mimic dental biofilms. For such 
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biofilms, there are no validated testing methods, as the methods validated by ASTM do 
not apply to this organism. Furthermore, they are mainly based on biofilm reactors 
requiring a vast amount of compounds, and therefore they are not suitable for pre-testing 
or screening. Thus, a methodological problem of dental biofilm research was 
encountered. 
This situation calls for developing and standardizing new biofilm methods that can be 
more widely applied to other biofilm-mediated conditions. Therefore, effort was invested 
into optimizing a new dental biofilm model.  Because a dental pathogen (A. 
actinomycetemcomitans ATCC 33384) was not optimized for studies, the experiments 
were started with model organism (S. aureus Newman), which was already optimized in 
96-well assay conditions. This way, assay settings were built piece by piece, by changing 
one component at a time. 
8.1 Effect of bisphosphonates on bacterial biofilms formed in liquid cultures in 96-
well plates 
8.1.1 Effect of bisphosphonates on Staphylococcus aureus Newman biofilms 
First, a preliminary bisphosphonate anti-biofilm assessment on model organism (S. 
aureus Newman) was performed in 96-well plates. This non-dental bacterium was used 
as a model organism because it is well known, widely used in first-tier screening studies 
and already optimized for this assay type (Sandberg et al. 2008; Sandberg et al. 2009; 
Skogman et al. 2012). Moreover, this strain is frequently used for an assay condition 
optimization and validation. In this experiment, exposed biofilms were stained with 
resazurin to detect biofilm viability. Resazurin concentration and incubation time were 
based on Sandberg et al. (2009). The effects of bisphosphonates on biofilm viability (at 
37°C, in aerobic conditions) are presented in Figure 16. Penicillin G, at a very high 
concentration (400 µM) was used as a control. It prevented 99.9% of biofilm viability but 
destroyed only 74.6% of formed biofilms. The chemotolerance of S. aureus biofilms to 
penicillin G has been demonstrated earlier (Skogman et al. 2012; Manner S, unpublished 
observation, 2015) indicating that the test succeeded. In contrast, none of the 
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bisphosphonates had any significant effect on biofilms when compared to the threshold 
value (hit limit).  
 
Figure 16.  S. aureus Newman biofilm viability when exposed to the bisphosphonates. 
The results of pre-exposure are drawn in white and post-exposure in gray. The hit limits 
are indicated with the dotted line for pre-exposure and with the solid line for post-
exposure assay. 
 
Each compound treatment was performed in six wells, except penicillin G which was 
applied in only four wells. The assay quality was appropriate (Z’ > 0.5; S/N > 5.5; S/B > 
9). In conclusion, bisphosphonates do not seem to have an effect on the Gram-positive 
model organism (S. aureus Newman). The results are similar to Kruszewska et al. (2002 
and 2012), where antimicrobial activity of alendronate (2002), clodronate (2002) and 
risedronate (2012) against S. aureus ATCC 6538P was tested without any effect. 
8.1.2 Effect of bisphosphonates on Aggregatibacter actinomycetemcomitans ATCC 
33384 biofilms 
Next, the same 96-well plate assay was conducted by changing the strain to a more 
relevant dental pathogen (A. actinomycetemcomitans ATCC 33384), which is a late 
colonizer in dental biofilms. Culturing conditions for this strain were adopted from Paino 
et al. (2011). These included the composition of medium (TSB-YE/Glc; TSB 
supplemented with 0.6% (w/v) yeast extract and 0.8% (w/v)), TSAD5 plates (TSA plate 
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supplemented with 5% defibrinated sheep blood) and incubation in microaerophilic 
culture conditions (at 37°C, in candle jars).  
Before proceeding to bisphosphonate susceptibility testing with this strain, it was pivotal 
to optimize biofilm formation time and resazurin staining conditions. Optimization of the 
formation time was performed by growing biofilms 24 and 48 hours (at 37°C in 
microaerophilic conditions) to assess the growth trend of biofilm biomass. This was 
carried out with crystal violet staining. Crystal violet was used because it does not require 
any strain-specific optimization. The relative absorbance units (RAU) of the 
measurement are presented in Figure 17. Crystal violet staining of other A. 
actinomycetemcomitans strains has been previously reported by Paino et al. (2011) and 
Massa et al. (2014), but not in 96-well plates.  
 
Figure 17. A. actinomycetemcomitans ATCC 33384 biofilm biomass after 24 hours (left) 
and 48 hours incubation (right). Biofilms are indicated with the grey circles and TSB-
YE/Glc-control with the white squares. The photos of biofilms (above) and TSB-YE/Glc 
(below) on the right were taken at the end of the staining process. 
 
Biomass formation was clearly detected after 24 hours. Thus, there was a significant 
signal in bacteria containing wells (grey circles) when compared to the background signal 
(white squares). Biofilm Z’-values were 0.16 and 0.12 for 24 hours and 48 hours, 
respectively. Based on this, a convenient biofilm formation time was chosen to be 24 
hours. The averages of biofilm relative absorbance units were 2.2 and 2.7 for 24 hours 
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and 48 hours, respectively. Other assay quality parameters were also appropriate (S/N > 
3.8; S/B > 8.5).  
As previously indicated, biomass quantification does not provide a complete view on how 
antibiotics affect biofilms. For instance, in cannot be conclusively stated whether the 
remaining biofilms are still alive since biofilm biomass measurement does not distinguish 
between live and dead organisms. Hence, it is essential to measure the amount of living 
cells in susceptibility trials. This is enabled by redox probes such as resazurin, but they 
typically require strain-specific optimization. Resazurin staining of other A. 
actinomycetemcomitans strains has been carried out by Paino et al. (2011) and 
Sreenivasan et al. (2003) (not in 96-well plates), but these experiments did not offer 
suitable information concerning stain incubation times. Thus, the next step was to 
optimize the resazurin incubation time and conditions for A. actinomycetemcomitans 
ATCC 33384.  
Suitable resazurin stain incubation time and conditions were optimized by comparing 
incubation in aerobic conditions (at RT, in the darkness for 45, 60, 85, 120 and 240 
minutes) and in microaerophilic conditions (at RT, in the darkness for 60 minutes). The 
optimization trials were performed first in aerobic conditions since these conditions were 
previously used for S. aureus Newman. Z’-values of these incubation experiments, 
indicating assay performance, are presented in Table 6. All of the incubation times 
provided sufficient result quality in terms of Z’-values. Therefore, the convenient time of 
60 minutes was selected for a further optimization trial, which was conducted in 
microaerophilic conditions (for 60 minutes), more relevant for A. actinomycetemcomitans 
ATCC 33384. While every incubation time-condition combination indicated suitable test 
quality parameters (Z’ > 0.5; S/N > 9; S/B > 3.7), 60 minutes in microaerophilic 
conditions (at RT, in the darkness) was chosen for further trials.  
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Table 6. The resazurin staining performance expressed as Z’-values for A. 
actinomycetemcomitans ATCC 33384. 
Minutes 
Z’-value in aerobic 
conditions 
Z’-value in microaerophilic 
conditions 
45 0.70  
60 0.65 0.67 
85 0.69  
120 0.67  
240 0.71  
 
For an additional confirmation that biofilms were indeed formed under the chosen 
conditions, FM imaging of LIVE/DEAD® BacLight™ stained biofilms was carried out. 
Fluorescence microscope imaging of other A. actinomycetemcomitans biofilm strains on 
different disk surfaces (using the same staining agents) has been reported by Massa et al. 
(2014) and Sánchez et al. (2011 and 2014), indicating that such imaging could be feasible 
also in this case. Thus, untreated and treated biofilms (at 37°C, in microaerophilic 
conditions) were stained with LIVE/DEAD® BacLight™ probe (Figure 18).  
 
Figure 18. The overlay FM images taken from untreated and pre-treated A. 
actinomycetemcomitans ATCC 33384 biofilms. The scale bars indicate a distance of 100 
µm. 
 
Biofilms for FM were grown in the same conditions as the ones where crystal violet and 
resazurin stainings were performed. A simple visual observation reveals the existence of 
living biofilms in the untreated stained wells. Living cells, indicating green fluorescence 
(SYTO® 9 stain), are predominant in the untreated (control) biofilms and are not 
quenched by dead cell-indicating red fluorescence (propidium iodide stain). On the other 
hand, biofilms pre-treated with 10 µM rifampicin and 25 µM chlorhexidine have the 
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opposite behavior where propidium iodide reduces SYTO® 9 in damaged cells, causing 
red fluorescence. This is a further confirmation that A. actinomycetemcomitans ATCC 
33384 biofilms are formed under the established conditions and that such biofilms are 
susceptible to the known antimicrobials. The results are addionally substantiated by 
viability inhibition values measured in similar pre-exposure conditions (at 37°C, in 
microaerophilic conditions) (Table 7).  
Table 7. Viability of A. actinomycetemcomitans ATCC 33384 biofilms when exposed to 
the control antibiotics of FM assay. 
Compound Hit limit (%) Viability inhibition (%) SD 
Rifampicin 10 µM 42.86 99.51 0.32 
Chlorhexidine 25µM 42.86 99.98 0.14 
 
After establishing suitable assay conditions, the final step was to study the strain 
susceptibility to bisphosphonates. Compound-exposed biofilms were stained with 
resazurin to detect biofilm viability. The optimized conditions (24 hours of biofilm 
formation, 60 minutes of resazurin staining time in microaerophilic conditions) were 
utilized. Bisphosphonate effects on biofilm viability are presented in Figure 19 (at 37°C, 
in microaerophilic conditions). The control compound rifampicin almost completely 
(~100%) prevented biofilm viability and destroyed 72.6% of formed biofilms. In contrast, 
none of the bisphosphonates had any significant effect on biofilms when compared to the 
threshold value (hit limit). For each bisphosphonate, treatment was performed in six 
wells. Rifampicin was applied in four wells. The assay quality was appropriate (Z’ > 0.5; 
S/N > 6.3; S/B > 3.9).  
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Figure 19. A. actinomycetemcomitans ATCC 33384 biofilm viability when exposed to 
the bisphosphonates. Pre-exposure results are drawn in white and post-exposure results 
in gray. The hit limits are indicated with the dotted line for pre-exposure and with the 
solid line for post-exposure. 
 
The results gained from resazurin staining were verified with crystal violet staining 
(results not presented). In conclusion, bisphosphonates do not appear to have an effect 
either on the Gram-positive model organism (S. aureus Newman) or the Gram-negative 
dental biofilm organism (A. actinomycetemcomitans ATCC 33384).  
8.2 Effect of bisphosphonates in combination with BAG on Aggregatibacter 
actinomycetemcomitans ATCC 33384 in a single-specie dental biofilm model 
Considering the objectives of this work, 96-well plate assays alone do not offer sufficient 
information for a number of reasons. First, 96-well plates are not ideal for solid samples. 
Thus, bioactive glass was not compatible with this assay. A further drawback is that the 
influence of planktonic bacteria cannot be ignored from the wells, introducing a potential 
result bias. Moreover, the medium is quickly exhausted due to the limited well space 
(Merritt et al. 2005). Finally, biofilms in 96-well plates are formed on polystyrene, which 
are not relevant formation surfaces for dental biofilms. 
The surface material issue can be circumvented by growing biofilms on coupons, which 
can be installed in either liquid cultures of biofilm reactors, or in solid-state cultures with 
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the Static Biofilm method. The drawback of biofilm reactors is that flow shear is 
significant. Assuming such conditions would be questionable for the present target 
environment, especially for periodontal pockets. Another similar issue is the small, ca. 1 
mL volume of saliva in the mouth. Methods containing large amounts of medium are not 
suitable in properly reflecting oral conditions.  
For a meaningful study of the bisphosphonate-BAG combination against dental biofilms, 
a different model needed to be introduced. This led to introduction of the single-specie 
dental biofilm model (Aggregatibacter actinomycetemcomitans ATCC 33384). This 
model was based on the Static Biofilm method, originally introduced by Charaf et al. 
(1999) and further developed by Oja et al. (2014). Here, relevant biofilm formation 
substrates, e.g. plexi glass and hydroxyapatite, could be utilized in low shear conditions 
relevant to the oral space. Additional strengths of this method include its reliability, 
simplicity and the fact that it requires only basic laboratory supplies (Charaf et al. 1999). 
The Static Biofilm method can be considered ideal for studying many kinds of treatments 
against biofilms.  
The drawbacks of this method are that it is quite laborious and time consuming. This is 
highlighted especially when a number of different treatments are tested, leading to poor 
suitability for high throughput screening. Hence, use of the Static Biofilm method is 
limited to study biofilms growing in specific locations (Oja et al. 2014). Still, it offers a 
simple and inexpensive tool for biofilm formation studies on different materials or in 
biocide susceptibility testing.  
Before starting bisphosphonate-BAG testing, it was pivotal to identify a relevant substrate 
material for dental applications, on which A. actinomycetemcomitans ATCC 33384 
biofilms could be formed. In addition to the relevance of hydroxyapatite 
[Ca10(PO4)6(OH)2] as the mineral component of dentine and bones (Pryor et al. 2009), both 
hydroxyapatite and plexi glass are employed as materials in dental implants. These two 
materials were compared to the reference substrate (glass). Thus, a quick comparative 
screen of A. actinomycetemcomitans ATCC 33384 attachment was carried out on 3 
different coupon materials (hydroxyapatite, plexi glass, glass) during 48 hours at 37°C in 
humidified microaerophilic conditions. The attached biofilms were quantified with log10 
of viable CFU counts (Figure 20) as in Oja et al. (2014).                                                                
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Figure 20. A. actinomycetemcomitans ATCC 33384 attachment on the different coupon 
materials (glass, plexi glass and hydroxyapatite) after 48 hours. 
 
In the conditions of the assay, bacteria were able to attach to all three surfaces. Highest 
viable counts were measured on the hydroxyapatite surface. Other A. 
actinomycetemcomitans strain biofilms have been grown on saliva-coated hydroxyapatite 
surfaces by Sánchez et al. (2014) in 24-well plates. They obtained similar biofilm 
attachment values (log10 ca. 6) after 48 hours of incubation, which are in agreement with 
present results. Thus, hydroxyapatite coupons were chosen for further studies. 
To test the bisphosphonate-BAG samples in this model system, additional aspects needed 
to been taken into account. One of them was the selection of a proper (negative) control 
material for bisphosphonates to be combined with BAG. Such a material is required to be 
inert (no intrinsic antimicrobial activity) and also to possess a similar particle size to 
bisphosphonates. The particle size equality is pivotal since small particles have higher 
surface area per volume, indicating increased attachment area for bacteria. One promising 
control candidate was inert glass. Commercially available inert glass is non-reactive and 
does not display any biological activity. However, different particle sizes are offered by 
suppliers. Therefore, the particle sizes of alendronate, etidronate, risedronate and 
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zoledronate and inert glass were measured with Flashsizer FS3D, and the values of the 
inert glass were compared to the values of the bisphosphonates (Table 8). The values of 
clodronate were acquired from Rosenqvist et al. (2013). The particle sizes are expressed 
as D10-, D50- and D90-fractile values, which denote that 10%, 50% and 90% of particles 
(respectively) are smaller than the presented size range. According to the D50-values 
(representing the median particle size), the acquired inert glass was deemed preliminarily 
suitable for the dental biofilm model. However, a verification of bacterial attachment to 
the inert glass beads was required. Attachment was tested with a combination of 550 mg 
of inert glass and 450 µl of saline on hydroxyapatite coupons. The log10 values were 7.75 
(SD = 0.18), which is expectedly a notable increase over the coupons. Thus, inert glass 
beads were chosen to be used as control in this two-component system. 
Table 8. The particle sizes of bisphosphonates and their control (inert glass beads) 
evaluated with Flashsizer FS3D.  
 
 
 
 
 
 
 
According to the measurements, risedronate particles were clearly the smallest, while the 
differences between other compounds were less significant. These differences in particle 
size between the tested compounds present an additional source of uncertainty for the 
following experiments. On one hand, low particle size may facilitate higher bacterial 
attachment (large surface area per volume). On the other hand, if bisphosphonates indeed 
participate in the production of anti-biofilm effects, a smaller particle size may accentuate 
this effect. To reduce this uncertainty, it would be optimal to test bisphosphonate samples 
of similar particle size. To acquire a similar partice size, e.g. a drug filter sieve could have 
been utilized. However, small compound amounts restricted this opportunity. 
With the developed dental biofilm model, the anti-biofilm effects of bisphosphonate-
BAG combinations were studied on A. actinomycetemcomitans ATCC 33384 biofilms 
during 48 hours at 37°C in humidified microaerophilic conditions (Figure 21).  
Compound D10 (µm) D50 (µm) D90 (µm) 
Alendronate 45 95 185 
Clodronate 80 160 230 
Etidronate 50 100 155 
Risedronate 20 35 50 
Zoledronate 45 80 125 
Inert glass beads  55 105 200 
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Figure 21. A. actinomycetemcomitans ATCC 33384 attachment on coupons covered with 
two-component samples. The samples were composed of 50 mg of bisphosphonates or 
inert glass beads (control) and 500 mg of BAG. The probability values were obtained by 
unpaired t-tests with Welch’s correction using GraphPad Software. Statistically 
significantly differences (p < 0.05) are marked with * and ns indicates not significant 
difference. 
 
It was observed that inert glass-BAG-treated coupons possessed more viable counts than 
untreated hydroxyapatite coupon (Figures 20 and 21). Again, the increased surface area 
is assumed to be more prone to bacterial attachment. However, the inert glass-BAG-
treated control coupons possessed more viable counts than all bisphosphonate-BAG-
treated coupons. Logarithmic Reduction (logR)-values, representing the reduction in 
bacterial viability (Equation 7), are presented in Table 9. The risedronate-BAG-
combination was the most active combination in reducing the bacterial biofilm formation 
(statistically significant difference, p < 0.05). Other combinations also reduced biofilm 
viable counts (statistically significant differences, p < 0.05), with the exception of 
clodronate-BAG, where no statistically significant changes were detected. The 
experiment was performed with triplicates.  
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Table 9. The logR-values of bisphosphonate-BAG-combinations, indicating the 
difference between the control and the compound samples. 
Combination logR 
Alendronate + BAG 1.16±0.03 
Clodronate + BAG 0.56±0.15 
Etidronate + BAG 1.73±0.11 
Risedronate + BAG 3.24±0.06 
Zoledronate + BAG 0.99±0.03 
 
A. actinomycetemcomitans ATCC 33384 has not been previously used in the Static 
Biofilm method. Attachment studies with the following strains have been reported: 
Staphylococcus aureus (Charaf et al. 1999; Buckingham-Meyer et al. 2007; Oja et al. 
2014), Staphylococcus epidermis (Oja et al. 2014), Escherichia coli (Oja et al. 2014) and 
Pseudomonas aeruginosa (Charaf et al. 1999; Buckingham-Meyer et al. 2007; Oja et al. 
2014). Thus, both Gram-positive and Gram-negative strains have been tested previously. 
However, previous studies utilize only aerobic bacterial cultivation conditions. Hence, 
both the strain (A. actinomycetemcomitans ATCC 33384) and growing conditions 
(microaerophilic) used in this method were novel aspects of this thesis. Another method 
for attachment studies is to grow biofilms on coupons by incubating them with bacterial 
suspension in well plates (Sánchez et al. 2014). 
Previous efficacy testing of compounds to eradicate biofilms formed on coupons biofilms 
has been tested. In one method, the biofilms were growth with the aid of the Static Biofilm 
(Charaf et al. 1999; Buckingham-Meyer et al. 2007; Blomqvist 2014). In another method, 
biofilms were formed on coupon surfaces by incubating coupons with bacterial 
suspension in well plates (Coraça-Huber et al. 2014; Drago et al. 2014). After biofilm 
formation, the coupons are removed and exposed to compounds. Hence, the method used 
in this thesis differs from these aforementioned, since the compounds were applied in the 
beginning of the incubation period. This pre-exposure mode in the Static Biofilm method 
is also a novel aspect of the present work.  
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8.3 Mechanistic insights of the actions of bisphosphonates and bisphosphonate-
BAG-combinations on bacterial biofilms 
Changes in pH may create a hostile environment for bacterial growth and can therefore 
be one reason associated to the antimicrobial effects of certain compounds or materials. 
This is a possible case with the bisphosphonate-BAG-combination. First, pH changes 
caused by the stand-alone bisphosphonates were tested. The same conditions were used 
as in the 96-well plate assays: 300 µM bisphosphonate solutions in TSB and TSB-YE/Glc. 
These mimic the conditions which S. aureus Newman (Figure 22) and A. 
actinomycetemcomitans ATCC 33384 (Figure 23) encountered in 96-well plate, 
respectively (subsections 7.2.1, 7.2.2, 7.2.3).  
 
Figure 22. pH-time series of 300 µM bisphosphonate solutions in TSB. 
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Figure 23. pH-time series of 300 µM bisphosphonate solutions in TSB-YE/Glc. 
 
As shown in Figures 22 and 23, the pHs of media (TSB and TSB-YE/Glc) remained close 
to the initial pH value 7 during the entirety of both measurements. The presence of 
bisphosphonates did not change this behavior. This strongly suggests that 
bisphosphonates do not have an intrinsic pH-altering effect. 
Next, pH changes were measured in the same conditions as A. actinomycetemcomitans 
ATCC 33384 encountered in the dental biofilm model. This included a combination of 
50 mg of bisphosphonates or 50 mg of inert glass beads combined with 500 mg of BAG 
and 450 µl of saline (Figure 24). As control, 550 mg of inert glass beads and 450 µl of 
saline were mixed. BAG as a stand-alone compound in saline has been observed to result 
in a pH increase to 9-10 during the first 72 hours (Rosenqvist et al. 2013). 
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Figure 24. pH-time series of combinations. ● = 50 mg alendronate and 500 mg BAG, ■ 
= 50 mg clodronate and 500 mg BAG, □ = 50 mg etidronate and 500 mg BAG, ○ = 50 
mg risedronate and 500 mg BAG, ♦ = 50 mg zoledronate and 500 mg BAG, ◊ = 50 mg 
inert glass beads and 500 mg BAG, + = 550 mg inert glass beads, x = saline. 
 
Due to the limited amount of available compounds, the pH measurements were performed 
only once. Furthermore, sample volumes were small, which caused difficulties in pH 
measurement stabilization. Increased compound amounts would provide better stability 
for the measurement probe. Saline pH remained neutral during the entire measurement.  
When pH measurements and logR values are considered together, some interesting 
observations can be made. Both BAG (Rosenqvist et al. 2013) and inert glass show an 
intrinsic tendency to raise the medium (saline) pH. However, it was noted that the 
bisphosphonates disrupt this process with a notable, temporary increase in acidity. This 
increase, in turn, is strongly compound-specific. Etidronate caused a brief but radical pH 
drop, while the moderate drop induced by risedronate was much longer lasting. These 
compounds also led to the greatest reduction in biofilm viability. In contrast, the least 
active compound, clodronate, caused only a mild decrease in pH. The decrease was also 
short-lived, as the medium became alkaline after only a couple of hours.  
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With these observations, it is reasonable to hypothesize that low pH is connected with 
decreased bacterial viability in the present case. Indeed, this is not surprising, considering 
the documented sensitivity of A. actinomycetemcomitans (Bhattacharjee et al. 2011) to 
acidity. They reported that this organism starts to lose its viability even in the mildly 
acidic pH. In their study, the drop of medium pH (from 7 to 6) reduced bacterial viability 
with logR of 2. An interesting aspect would be how the lowered pHs caused by the most 
effective bisphosphonate-BAG-combinations affect the base pH of crevicular fluid (7.5–
8.7) (Bickel et al. 1985). This analysis could provide information on whether these 
combinations have adverse effects on oral tissues. 
It is pivotal to note that the different bisphosphonate particle sizes may have an impact 
on pH behavior. A smaller particle size may induce a more radical pH change, causing a 
more hostile environment for bacteria. Thus, for determining the rank order for 
bisphosphonate-BAG combinations, additional tests with similar bisphosphonate particle 
sizes should be performed. 
Despite the evident correlation between pH decrease and lowered biofilm viability, it is 
still possible that differences in the chemical structure of bisphosphonates are also 
influential. However, this factor cannot be evaluated in the present study. Considering the 
molecular weights and functional groups of the bisphosphonates, no clear correlation with 
biofilm viability is established. 
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9 CONCLUSIONS AND FUTURE PERSPECTIVES  
The research objectives of this work were to investigate anti-biofilm effects of 
bisphosphonates alone and combined with bioactive glass, and to optimize the methods 
which were utilized. First, the anti-biofilm effects of five 300 µM bisphosphonates 
(alendronate, clodronate, etidronate, risedronate and zoledronate) solutions were assessed 
on a model organism (S. aureus Newman) in 96-well plates. It was observed that the 
compounds did not have any intrinsic anti-biofilm effect. Testing in 96-well plates was 
conducted with a relevant periodontal strain (A. actinomycetemcomitans ATCC 33384). 
Several assay condition optimization trials were performed before proceeding to 
susceptibility trials. This optimization comprised testing of suitable biofilm formation 
time (24 h), resazurin probe incubation time (60 min) and resazurin incubation conditions 
(microaerophilic). The following susceptibility tests confirmed the lack of intrinsic anti-
biofilm activity on the strain.  
After 96-well plate assays, bisphosphonate-BAG tests were introduced. These were 
performed with a single-specie (Aggregatibacter actinomycetemcomitans ATCC 33384) 
dental biofilm model, which was based on the Static Biofilm method. Again, assay 
condition optimization was required. Hence, different coupon materials for biofilm 
growth were compared, which led to the use of hydroxyapatite coupons in further 
investigations. Particle size measurements were performed to determine a suitable 
material for bisphosphonate replacement in control samples (inert glass). Utilizing the 
optimized method, the susceptibility of biofilms to bisphosphonate-BAG samples was 
investigated. In these assay conditions, the risedronate-BAG-combination (statistically 
significant difference, p < 0.05) was the most effective. Other combinations also reduced 
biofilm viability (statistically significant differences, p < 0.05), with the exception of 
clodronate-BAG, where the change was statistically insignificant. However, it is notable 
that the bisphosphonate particle sizes were different. Risedronate particles were clearly 
the smallest, while the differences between other compounds were less significant. 
Efficacy of the bisphosphonate-BAG combinations could be connected to temporal 
changes in pH. This observation is supported by recent literature where A. 
actinomycetemcomitans has been deemed highly sensitive to acidity. However, 
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establishing the rank order of bisphosphonate-BAG combinations would require 
experiments with equal bisphosphonate particle sizes.  
This project included some novel aspects. For the first time, A. actinomycetemcomitans 
ATCC 33384 was tested in 96-well plate assay, stained with resazurin, crystal violet and 
imaged with fluorescence microscopy. It was also introduced as a new strain for the Static 
Biofilm method. Previous susceptibility testing of biocidic compounds with the method 
has only been performed by using samples in liquid form. Here, solid samples were 
included as a novel feature in the field. Usability improvements, such as the double filter 
paper layer, were developed for the method. Furthermore, new coupon materials were 
introduced.  
All of the experiments were performed using mono-species models. Thus, future studies 
could introduce multi-species biofilms to reflect the periodontal biofilm status in a more 
realistic manner. These would comprise components of all biofilm stages: pioneer, early, 
intermediate and late colonizers. The Static Biofilm assays were performed only by using 
a single bisphosphonate concentration. Different concentrations could be investigated to 
clarify the concentration-response relationship. During this thesis, only perfunctory 
knowledge of the mechanism of action was obtained with pH measurements. Other 
mechanistic studies can be implemented in the future to supplement the information 
provided by the present pH measurements. One such example is to expose A. 
actinomycetemcomitans ATCC 33384 to a range of pH-controlled solutions. This could 
potentially reveal other, additive explanations for anti-biofilm activity. In addition, e.g. 
proteomics can be utilized to explore the mechanism of action further. 
For in vivo animal models, there is little information available regarding the effects of 
combination products to periodontal status parameters, e.g. alveolar bone level. Such 
models could further clarify how the promising bisphosphonate-BAG combinations 
affect periodontal parameters as well as periodontopathogen levels in infection models. 
At the same time it could also be investigated whether the lowered pHs caused by 
bisphosphonate-BAG-combinations are not harmful to oral tissues. It should be noted that 
in addition to anti-biofilm studies, combination effects on osteoclast and osteoblast 
behavior should be studied for a more comprehensive understanding of the subject. 
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